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Summary
Thirty two children ( twenty one boys and eleven girls ) whose ages ranged 
from 2.17 to 17.94 years were identified as having growth hormone 
deficiency. Of these, nineteen ( fourteen boys and five girls ) had idiopathic 
growth hormone deficiency, while in thirteen ( seven boys and six girls ) 
the growth hormone deficiency was due to cerejbal tumours either sui 
generis as in craniopharyngioma or idiopathic following operation and 
postoperative cranial irradiation.
Assays of plasma somatostatin and amino acid concentrations were made
on each patient three times, firstly at the time of the withdrawal of
cadaveric growth hormone, again at the reintroduction of recombinant
growth hormone nine months later and finally after one year's treatment
with the recombinant growth hormone.
%
The patients in the idiopathic group fell into two categories, mainly those 
whose plasma somatostatin concentrations were either abnormaly high or 
at a high normal concentration, and those in whom the plasma 
somatostatin concentrations were normal. Those with normal plasma 
somatostatin concentrations had a better catch-up growth than those 
whose plasma somatostatin concentrations were high.
In those children with cerebral tumours the plasma somatostatin 
concentrations were uniformly within normal limits irrespective of their 
growth response to the recombinant growth hormone treatment.
All the children during the off-growth hormone period had reduced rate 
of linear growth and plasma amino acid concentrations compared with 
both the cadaveric and recombinant growth hormone periods. On the
1
other hand the recovery in both linear growth velocity and plasma amino 
acid concentrations was greatest in those children whose plasma 
somatostatin was normal.
Thus normal growth hormone and low  plasma concentration of 
somatostatin are associated with a normal or high plasma amino acid 
concentrations, a situation advantageous to the linear growth.
Since the interrelationship between growth hormone, somatostatin, 
insulin like growth factors and linear growth are now clearly linked, 
immunization against somatostatin (in those children with high 
somatostatin concentration) or the concurrent administration of IGF-1 
might be explored in the treatment of growth hormone deficiency.
It is concluded that firstly, the high plasma concentrations of somatostatin 
militate against an optimum response to administered growth hormone 
and the concurrent fall in plasma amino acid concentrations may be 
contributary to a reduced osseous and muscle growth.
Secondly, that children who do not respond to growth hormone therapy as 
expected should have their plasma somatostatin concentration assayed 
before increasing the dosage of the expensive recombinant growth 
hormone.
Thirdly, it may be that even in children with short stature whose growth 
hormone status is normal, a high plasma somatostatin concentration is 
contributing to the short stature.
It is proposed that assay of plasma somatostatin is mandatory in the 
investigation of children with short stature.
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CHAPTER ONE
Introduction
Growth and especially its control is a complex and controversial 
phenomenon. It represents a profound interaction between genetic, 
hormonal and nutritional influences, and is the result of a multitude of 
processes which are controlled by neural and humoral mechanisms. 
Growth in effect is due to increase in total cell number (hyperplasia), in cell 
size (hypertrophy) and in the amount of intracellular material.
In this introduction I will review in general terms the present under­
standing of these mechanisms before embarking on a detailed analysis of 
the finer aspects of the subject relative to the work presented here.
Historical review
The earliest thoughts on there being a substance related to growth and its 
assignment to the pituitary gland as its origin has a historical interest but 
the real association of linear growth and the pituitary gland came as a 
result of Crow and his colleagues (1) who removed the pituitary glands 
from dogs and observed thereafter the failure of linear growth. The second 
phase was the observation that pituitary extracts when injected 
intraperitoneally into rats resulted in acceleration of their body growth (2). 
It was a short step to the purification of the earlier crude extracts and credit 
goes to Li and Evans (3 ) who isolated from bovine anterior pituitaries in a 
highly purified form a growth promoting substance which was named 
growth hormone. Unfortunately a human hypopituitary dwarf was given 
this bovine growth hormone with disappointing results in terms of linear 
growth and nitrogen retention (4). The explanation for this failure was later 
found in the fact that human and bovine growth hormones differ from
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each other in physicochemical nature (5, 6). Extracts from human pituitary 
glands given to humans was found to stimulate linear growth(5). Thus 
species specificity was established as far as growth hormone was concerned
CJ8 )•
The molecular structure of growth hormone has now been determined (9) 
and its exact amino acid sequence shown to be 191 amino acid residues 
containing two disulphide bridges between residues 53 and 165 and the 
other between residues 182 and 189 (10). It is a globular protein with a 
molecular weight of 22,000 (22K) (Figure 1.1). A smaller 20K variant is also 
present in the circulation but is less predominant, and is identical to the 
major form of hGH except for a deletion of a 15 amino acid segment, 
residues 32-46 of hGH. Other components with molecular weights of 45K, 
30K, 16K, 12K (11,12,13) are also present in the circulation. It may be that 
some forms of short stature are due to the 20K variant or other less 
bioactive forms of growth hormone.
In February 1985 a patient who had been receiving human growth 
hormone died with a clinical illness of progressive dementia and other 
neurological features of Creutzfeld-Jacob syndrome (14). A second patient 
was reported in April 1985, followed by yet a third report of the disease in a 
24 year old man who had received growth hormone for life-long 
hypopituitarism (15).
Since the introduction of human growth hormone as a treatment 
approximately 2000 children in the United Kingdom and 10,000 children in 
the United States of America have received this product. Therefore four 
cases of Creutzfeldt-Jacob disease in 12,000 patients represents an 
immensely elevated incidence over that in the general population. When
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the age of the victims all under 35 years is also considered, it is impossible 
not to suggest a causal link between growth hormone and Creutzfeldt- 
Jacob disease. This condition is world wide and has a reported incidence of 
one per million of the population per year. It affects the sexes equally, with 
the peak incidence of about 55 years of age, and is quite uncommon before 
the age of 30 years. Although its exact mode of transmission is unknown, 
it is thought to be transmitted via proteinaceous infectious particles or 
prions (16). The transmitting agents have also been labelled "slow 
viruses"but this could be a misnomer, for they contain no nucleic acids 
and unlike conventional viruses prions are extraordinarily difficult to 
inactivate, being resistant to formalin treatment, to 70 percent ethyl 
alcohol, to radiation, heat and ultraviolet light. They are however 
destroyed by 2N sodium hydroxide (15). Iatrogenic transmission of the 
disease has followed corneal transplantation and has been acquired from 
contaminated instruments used in neurosurgical procedures (17,18). 
Interestingly the scare came at a time when the demand for growth 
hormone was steadily exceeding supply and commercial (pharmaceutical) 
companies such as Eli Lilly, Kabi Vitrum and Serono were pressing ahead 
with research directed to producing a synthetic growth hormone by 
recombinant DNA techniques. Human growth hormone was 
immediately withdrawn as a treatment in Britain by May 1985, and 
patients were therefore without treatment until the new product became 
available in January 1986. This was methionyl growth hormone.
The principle of this technique is that the plasmid of the bacterial cell is 
opened and the DNA-containing strand to be cloned is inserted into it. 
This strand is derived from the human pituitary cell. The recombinant 
plasmid is inserted into the bacteria (E-coli) which is now transformed to
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synthesize human growth hormone. Recent research has resulted in an 
amino acid sequence identical to human growth hormone (19,20). Its use 
in clinical practice shows that it has all the attributes of the former 
cadaveric material but with remarkably few of the disadvantages of that 
product.
Biological actions of growth hormone
The actions of growth hormone are many and not all of them are known. 
Some of the recognised actions are on fat, carbohydrate, and protein 
metabolism. On fat it causes lipolysis and this was once thought to be due 
to a lipid mobilizing peptide, a moiety of the growth hormone molecule. 
The net effect is to raise the plasma lipid level and so facilitate the uptake 
of free fatty adds by musde as a source of energy (21).
On carbohydrate metabolism long term effects of growth hormone are to 
raise plasma glucose concentrations through a combination of glucose 
production and decreased utilization by limiting glucose transport within 
the cells. This hyperglycaemic effect takes place after several hours leading 
to a relatively insulin resistant state which produces hyperinsulinaemia if 
the growth hormone concentration remains high. The short-term  
administration of growth hormone exerts an insulin-like effect which 
results in a modest and transient degree of hypoglycaemia (22).
On protein metabolism the effects of growth hormone are better 
understood by giving growth hormone to growth hormone deficient 
patients. There is an induced nitrogen retention for protein synthesis. 
This action is c-AMP-dependent. Intracellular transport of amino adds is 
increased as well as mRNA (23) which leads to an increase in the organ 
size and differentiation as well as increasing functional capacity.
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On mineral metabolism growth hormone leads to a large retention of 
potassium and phosphate intracellularly. In growth hormone deficiency 
states, growth hormone administration leads to increased concentrations 
of phosphate. Retention of sodium is less than that of potassium. Serum 
calcium concentrations are not increased, although there is an increased 
urinary excretion of calcium, related to an increase in calcium absorption 
(24). Sometimes during treatment a negative calcium balance may occur, 
the aetiology of which is unknown. Table 1.1 summarises some of the 
biological actions of growth hormone.
Important to this thesis is the action of growth hormone on skeletal 
growth. In association with locally produced IGF-I (25) growth hormone 
acts directly on the chondrocytes of the epiphyseal plate to cause 
proliferation with the formation of palisades (26,27). These cells ossify to 
be incorporated into the metaphysis of the bone, so lengthening it.
Pertinent to this work is also the role of growth hormone and IGF-I in 
nutrition. For example, in kwashiorkor there are elevated concentrations 
of growth hormone and depressed concentrations of IGF-I (28). The 
increase in circulating growth hormone is due to increased production 
rather than a decrease in the rate of clearance.
In* patients with diabetic hyperglycaemia there is increased growth 
hormone secretion, probably due to relative intracellular starvation 
(glucopenia) due to the lack of insulin. Badly controlled diabetic children 
are frequently short statured especially in association with hyper as well as 
hypoglycaemia and clearly the interactions between cellular nutrition, 
circulating blood sugar concentrations and growth hormone secretion 
account for this observation.
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Table 1.1 Biological actions of growth hormone
GH
Adipose tissue 
Deaease glucose uptake 
Incxease lipolysis
Deaease adiposity
Muscle
Deaease glucose uptake
Incxease a.a uptake 
_ pro te in  syn thes i s
Inaease lineax body mass
Livex
Inaease RNA synthesis 
= Fxotein synthesis 
= Gluconeogenesis
Somatomedins
bone, heaxt, lung, kidney...etc
Inaease pxotein synthesis 
= HIM A synthesis
= DNA synthesis 
= Cell size and numbei
Increase organ size 
Increase organ funct ion
chondxocytes
Incxease a.a uptake
= Piotein synthesis
= RNA synthesis
= DNA synthesis
= Collagen
= Condxoitin sul phate
= Cell size and numbex
Incxease lineax gxowth
Growth hormone receptors
In its action growth hormone becomes attached to a specific membrane 
receptor. This receptor consists of three components: an extracellular 
portion which presumably binds growth hormone, a transmembrane 
portion and a cytoplasmic portion. The receptor has a value of 130,000 
Daltons and is heavily glycosylated. It is a unique protein without 
similarity, and is highly specific for human growth hormone (29). 
Undoubtedly this explains the earlier mention of lack of response when 
bovine growth hormone was administered to a child with growth 
hormone deficiency. Cells secrete growth hormone binding proteins into 
the circulation. This circulating binding protein is similar to the receptor 
protein and may also be the extruded extracellular portion of the 
membrane receptor. In patients with Laron dwarfism there is a lack of this 
circulating binding protein and this has led to the conclusion that they 
may have a lack of the receptor for growth hormone (30,31).
Insulin-like growth factors
Two such are identified, namely IGF-I and IGF-II. It was formerly thought 
that the liver was the main source of supply to the circulating plasma pool 
as far as IGF-I is concerned. This is still correct but it is now recognized that 
IGF-I is elaborated at the site of action of growth hormone where it 
mediates growth hormone action (25) and at least locally produced IGF-I 
has its local action before entering the circulating pool.
These IGF's are secreted in response to the circulating levels of growth 
hormone and circulate bound to high affinity proteins. IGF-I is more 
growth hormone dependent than IGF-II. There are two receptors for the 
IGF's -  one for IGF-I which binds it preferentially and is similar to the
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insulin receptor but binds also IGF-II and insulin although with less 
affinity.
These IGF-I receptors are associated with the growth promoting actions of 
growth hormone. The IGF-II receptors are structurally different; they bind 
IGF-D preferentially but also IGF-I with less affinity (32). IGF-II receptors 
are associated with other somatic actions of growth hormone.
Interestingly, while growth hormone stimulates increased production of 
IGF-I, the IGF-I inhibits the secretion of growth hormone directly acting on 
the pituitary and also indirectly through the stimulation of somatostatin 
secretion in the hypothalamus forming a part in the regulation of growth 
hormone secretion as will be seen later.
Growth hormone secretion throughout life
In fetal life growth hormone is detectable in the pituitary at the 5th to the 
7th week of gestation (33), but its presence and accumulation is not 
thought to be responsible for fetal growth. Fetal growth has been related to 
nutritional circumstances mediated through insulin and the IGFs. At 
birth the plasma concentration is greater than the corresponding maternal 
level but it declines after the first 48 hours of life (34).
In childhood, the fasting growth hormone level is lower than that of the 
newborn, but higher than the adult value. During the 24 hours of the day 
there are spontaneous peaks of plasma growth hormone higher and more 
frequent than in adults (35). Also tall children secrete more growth 
hormone than small children; the rates of growth of the tall child and the 
child with pituitary gigantism being similar but in pituitary giants 
associated with massive amounts of growth hormone beyond that of the 
normal tall child. The manner in which the growth hormone is secreted
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in the two instances is different. The tall child has short bursts of high 
amplitude, while the child with pituitary gigantism has longer bursts of 
lower amplitude (36).
In pubertal children the basal plasma growth hormone concentration is 
not significantly different from that of adults but more peaks may occur 
during the day with greater amplitude during the night than occur in 
adults. The diurnal pattern of growth hormone secretion shows peaks 
these being associated with food ingestion, exercise and REM sleep. This 
fact is made use of when testing children for neurosecretory growth 
hormone deficiency.
Control of Growth Hormone Secretion
Preformed growth hormone in the pituitary is released under the 
influence of growth hormone releasing hormone. This substance is a 
small peptide elaborated by nuclear aggregates in the hypothalamus. The 
substance is delivered to the infundibular stalk via the long axons of these 
cells. From the infundibulum the releasing hormone is taken up by the 
long pituitary portal vessels and delivered to the eosinophil cells in the 
anterior hypophysis, thus stimulating growth hormone release. Another 
small peptide also elaborated in hypothalamic aggregates of cells and 
reaching the pituitary by the same means is somatotrophin release- 
inhibiting factor (SRIF). At the pituitary cell level SRIF damps down the 
action of the releasing hormone, so smoothing the continuous growth 
hormone secretion. SRIF is now termed somatostatin (37).
Growth hormone releasing hormone has been characterized and produced 
by recombinant DNA techniques. It is now available for clinical use -  
diagnostically at present and to a lesser extent therapeutically.
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Somatostatin not only inhibits growth hormone secretion stimulated by 
GRF but under different temporal conditions, somatostatin may act in a 
paradoxical positive manner to sensitize the pituitary growth hormone 
response to GRF (38). This co-operative interaction may well be necessary 
to optimize pulsatile growth hormone release. Linear growth in children 
is recognized to be associated intimately with the pulsatile nature of 
growth hormone release as already mentioned.
Growth hormone deficiency
The identification of children with growth hormone deficiency is now  
according to nationally accepted tests. Children to be tested are identified 
either because they are in stature less than the third centile (usually < 2.5 
SDs) or because over a twelve month period they have a height velocity 
below the 25th centile (46). Other systemic, genetic, chromosomal, osseous 
and endocrine diseases are excluded as a cause of the short stature before 
specifically testing for growth hormone reserve.
Causes of growth hormone deficiency
When considering this subject it is patently obvious from the foregoing 
discussion that a failure to synthesize growth hormone will result in 
growth hormone deficient short stature. Failure to synthesize the 
hormone could be inherited as an autosomal dominant or recessive trait 
(39), with pituitary aplasia or hypoplasia or destruction of the pituitary 
gland during operative procedures such as removal of a prolactinoma.
Secondly the hypothalamic stimulus of growth hormone releasing 
hormone may be absent and although the pituitary may contain adequate 
growth hormone, none of it can be released. Herein is an interesting 
observation. Induced hypoglycaemia acting at the hypothalamic level
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through gluco-privation may fail to stimulate the release of growth 
hormone releasing hormone. Additionally hypoglycaemia also stimulates 
the release of corticotrophin releasing hormone with a resultant rise in 
ACTH and plasma cortisol. Thus during hypoglycaemia a rise in plasma 
cortisol without a significant rise in growth hormone would indicate 
deficiency of growth hormone releasing hormone. Other factors which 
might destroy the nuclear aggregates producing growth hormone releasing 
hormone are, irradiation (the hypothalamus being more sensitive to the 
effects of radiation than the pituitary) (40), tumours, infiltrations 
(reticuloendotheliosis) and other causes. Table 1.2 shows the common 
causes of growth hormone deficiency.
Somatostatin is well recognized as an inhibitor of growth hormone 
secretion. Were somatostatinomata common in children, short stature 
would be a likely accompaniment. But less gross increases in somatostatin 
can inhibit growth hormone release and the degree of inhibition may 
reduce plasma growth hormone concentrations. A secondary effect of 
somatostatin is to reduce the concentrations of plasma amino acids and it 
could be that a combination of these two facts could restrict growth.
A psychosocial aetiology for growth hormone deficiency is also recognized. 
In these children depressed levels of stimulated growth hormone 
normalize when the child is placed in an improved social circumstance. 
The mechanism here is unclear, and there is no response to GH treatment; 
the children restart growth by changing their environment (41).
Finally here it must be mentioned that other endocrine substances such as 
glucocorticosteroids inhibit release of growth hormone; this is seen in 
Cushing's disease and Cushing's syndrome (42). In terms of glucocorticoid
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Table 1.2 Common causes of growth hormone deficiency
1. Congenital.
Hereditary autosomal recessive 
autosomal dominant 
idiopathic GHRHD
Developmental defects
pituitary aplasia.
pituitary hypoplasia.
midline anomalies
2. Acquired. Tumours.
Irradiation
hypothalamic 
pituitary, 
other intracranial
Infection. meningitis
encephalitis
Infiltration. histiocytosis X 
haemochromocytosis.
Injury. perinatal insult, 
head injury.
3.Transient. peripubertal. 
psychosocial, 
primary hypothyroidism.
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therapy it is stated that replacement therapy should ideally not exceed 10-15 
mg hydrocortisone per m2 per day. However it has been postulated that 
glucocorticoids inhibit growth hormone secretion above the level of the 
pituitary (43). In panhypopitllitary multiple replacement therapy is 
required with growth hormone, ACTH or hydrocortisone, thyroxine and 
possibly the gonadotropins.
It has been quoted that in a general population the incidence of 
endogenous growth hormone deficiency may range from 1 in 3700 
children to 1 in 30,000 (44-45). This disparity may reflect the variations in 
diagnostic criteria used by different investigators.
Provocative tests for diagnosis of growth hormone deficiency
(a) Most simple is the post-prandial (3 to 4 hours after glucose ingestion: 1.4 
g/kg) plasma growth hormone concentration. Values above 15 m u/L are 
normal.
(b) The post exercise test requires the patient to undertake vigorous 
exercise for a period of 25-30 minutes. Concentrations of plasma growth 
hormone reach upwards of 20 m u/L  in more than 50 to 90 per cent of 
normal children tested
(c) The sleep test. It is known that during REM sleep growth hormone is 
secreted in high concentration. In 60 to 70 per cent of normal children 
REM sleep concentrations exceed 20 m u/L (47-48).
(d) Arginine infusion test (0.5 g/kg; maximum dose 40 gm). The arginine 
hydrochloride (10 per cent solution) is given intravenously at a constant 
rate over 30 minutes. Blood is taken at 30 minute intervals over 2.5 hours. 
In some 85 per cent of normal children, concentrations of plasma growth 
hormone greater than 15 m u/L  are achieved. (In growth hormone
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deficient children there is a risk of hypoglycaemia and blood glucose 
concentrations should be monitored.) In a sense this is an important test to 
this thesis, although it was not used to identify any of the children, the 
subjects of this work. But certain amino acids may facilitate the release of 
growth hormone by suppressing somatostatin; this subject will be dealt 
with later.
(e) Glucagon test. Glucagon (30-100 micrograms per Kg up to a maximum 
of 1 mg) normally gives rise to a plasma concentrations of growth 
hormone exceeding 15 m u/L after 120 minutes in 75 to 80 per cent of 
healthy children. Concentrations less than 15 m u/L indicate deficiency of 
growth hormone reserve (49).
(f) Clonidine Test. This alpha adrenergic receptor stimulant facilitates 
growth hormone release. When given orally (0.15 m g/m ^) peak 
concentrations of plasma growth hormone are noted between 90 and 120 
minutes after ingestion (50).
(g) The Insulin Tolerance Test ( ITT ). This test is by far the most reliable 
and it was the first test to be used. Historically it was referred to as the 
insulin unresponsiveness test before growth hormone could be measured 
in the plasma. Delayed recovery from hypoglycaemia till 2.5 hours post 
injection of insulin (I.V. 0.1 units per kg) indicated lack of growth 
hormone reserve. Nowadays peak plasma concentrations of growth 
hormone 30 minutes after the nadir of blood glucose are expected. 
Absolute growth hormone deficiency is indicated by peak concentrations of 
plasma growth hormone less than 7.0 mU/1, concentrations from 7.0 to 15 
mU/L are regarded as indicating partial growth hormone deficiency, while 
normal concentrations are greater than 15.0 mU/1 and they may reach 40- 
50 mU/1. This test has become the backbone of investigation of growth 
hormone deficiency although somewhat m odified in im m ediate
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prepubertal and pubertal children by the administration of testosterone 
(im) or oestrogen (orally) to the respective sexes. This practice is referred to 
as the priming procedure. The sex hormone is thought to make the 
hypothalamus more sensitive to glucoprivation and the basis for the 
practice is the well recognized fact that during normal puberty the growth 
spurt is associated with both an increased plasma concentration of growth 
hormone and of sex hormones.
Factors stimulating and inhibiting growth hormone secretion
It is well recognized that preformed growth hormone in the pituitary is 
released under certain physiological, pharmacological and pathological 
states. These have been well summarized in Table 1.3.
Additionally there are factors of similar type which inhibit the release of 
growth hormone. These are classified as under Table 1.4
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Table 1.3 Factors stimulating growth hormone secretion.
Physiological Pharmacological Pathological
1. Spontaneous 1. Hypoglycaemia 1. Acromegaly
2. Sleep 2. Amino acids 2. Starvation
3. Stress - physical 3.Hormones: glucagon 3. Protein deprivation
- psychosocial oestrogen 4. Anorexia nervosa
4. Exercise ACTH 5. Renal failure
5. Postprandial 
hypoglycaemia
vasopressin
6. Fasting 4. Monoamines: L-dopa 
propranolol 
epinephrine 
serotonin
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Table 1.4 Factors inhibiting growth hormone secretion.
Physiological Pharmacological Pathological
1.Postprandial 
hyperglycaemia.
l.Phentolamine 1. Acromegaly;
2.Elevated fatty acids. 2.Chlorpromazine L-dopa
3.Elevated GH levels. 3.Theophylline. phentolamine
4.Somatostatin. 4.Morphine. apomorphine
5.Depot-ACTH. somatostatin
6.Glucocorticoids. 2.Hyperthyroidism
3.Hypothyroidism.
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Somatostatin
Historical Aspects
While searching for a hypothalamic factor capable of releasing growth 
hormone from the anterior pituitary a substance which inhibited growth 
hormone release from rat anterior pituitary was unexpectedly detected (51). 
This finding led these workers to suggest that the secretion of growth 
hormone from the pituitary was regulated by two different interacting 
neurohumoral factors, one stimulatory and the other inhibitory and both 
under the control of the nervous system. Later on this substance was 
isolated and characterized from ovine hypothalami (52), it was found to be 
a tetradecapeptide with 14 amino acid residues, cyclic in structure and 
joined by two intramolecular disulphide bonds between the two cysteine 
residues at position 3 and 14 (Figure 1.2).
Subsequently, the tetradecapeptide was isolated from porcine hypothalami 
and characterized (53). It was isolated from the pancreas of anglerfish (54) 
and it was found also in rat pancreas(55). Indeed it has been isolated from 
human adrenal medulla and pheochromocytoma, this being the first 
occasion when non-physiological tissue was analysed (56). Following these 
very basic discoveries and the synthesis of somatostatin in quantity, many 
researchers have administered the peptide to both animals and humans to 
study its biological activities and its precise mode of action.
Somatostatin was at first referred to as growth hormone release-inhibiting 
factor (GH-RIF) or somatotrophin release inhibiting factor (SRIF). Now all 
these names seem inappropriate since somatostatin has been isolated from 
cells unrelated to growth hormone regulation as we shall shortly consider.
However its early isolation from animal hypothalami and more precisely
43
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from cell aggregates located mainly in the m edian eminence, 
periventricular and medial preoptic areas of the anterior hypothalamus 
justifies the original name (57,58,59).
Distribution of somatostatin
Reliable methods for detection and quantitation of somatostatin are now 
widely in use. By immunocytochemistry somatostatin can be localized in 
tissues, but only if the somatostatin is immunoreactive. Radioligands 
specific for somatostatin receptors (using SS-14 analogues, SS-28 analogues 
or analogues of the stable octapeptide SMS 201-995) has facilitated 
somatostatin detection in post-mortem material either by binding 
techniques or by visual detection with autoradiography. Somatostatin in 
biological fluids and extracts may not only be detected but quantified by 
radioimmunosassay. Somatostatin immunoreactivity has now been 
detected in the central nervous system, in the gastrointestinal tract, in the 
genitourinary system, heart, eye, thyroid, thymus, skin and in some 
neuroendocrine tumours (60,61,62,63). More detailed comment will be 
made on some of these findings as seems appropriate to this work. But 
before doing so it is of interest to note that somatostatin cells display 
characteristic morphological features such as cytoplasmic elongations 
suggesting a local or paracrine role. The cells are round in shape, have a 
flocculent matrix and closely opposing limiting membranes.
In Brain Tissue
Somatostatin is present in the hypothalamus, the cerebral cortex, and the 
hippocampus. Earlier reference has been made to such specific sites as the 
median eminence, periventricular and preoptic areas. It is present in cells 
which are part of intrinsic local circuits but also in long axons of other cells
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which suggest a projection activity to other areas from where the cells are 
located. Recently it has been shown that somatostatin is consistently and 
selectively depleted in the cerebral cortex of patients with Alzheimer's 
disease but localized in the characteristic birefringent plaques and 
neurofibrillary tangles so typical of this disease (64&65). This is of extreme 
interest for Alzheimer's disease is a degenerative disease with the clinical 
picture of deteriorating memory, reason, judgement and will, and is seen 
most often in the elderly. Presumably post-mortem examination of the 
cases of Creutzfeldt-Jacob disease 'due' to growth hormone administration 
did not reveal plaque formation in the brain. Also the ataxic features of 
the Creutzfeld-Jacob disease are not features of Alzheimer's disease. 
Nonetheless while the long tract pathologies of the two conditions may be 
different, the dominating features are similar and these are related to 
cortical function particularly of the anterior lobes. It is in the cortex that 
most somatostatin immunoreactivity has been detected. The question 
now is whether or not the early preparations of human cadaveric growth 
hormone recognized as being significantly contaminated with other 
hormones like TSH, LH and FSH also contained pituitary somatostatin. 
This somatostatin could have acted antigenically in the recipients to form 
antibodies to the cortical cells elaborating somatostatin. It is known that 
there are somatostatin receptors on the thyrotrophs and lactotrophs of the 
pituitary (66,67). There are some ampoules of the early UK human growth 
hormone still in the laboratories of the Department of Child Health and it 
would be of extreme interest to re-analyse that material with somatostatin 
content in mind for it may be a more plausible theory than the prions of 
Creutzfeld-Jacob could be. In Huntington's Chorea there is an increase of 
somatostatin in the caudate nucleus which is not of local production but
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rather delivered by long fibres from elsewhere to the nucleus. The 
significance of this is as yet uncertain (68).
In the human fetus, somatostatin has been found in the hypothalamus as 
early as 16 weeks gestation (69). This is not surprising for until then is the 
period of cell differentiation and organogenesis. But noxa which inhibit 
organogenesis could readily inhibit the cerebral cortical and hypothalamic 
acquisition of somatostatin synthesis and thus may give rise to as yet 
undetermined cerebral malfunctioning. Somatostatin immunostaining 
cells and fibres are found throughout the spinal cord. This system appears 
prenatally. Activity is greatest in the posterior horns and columns and is 
related to cells rather than fibres (70).
In Gastrointestinal Tissue
Immunoreactive somatostatin can be extracted from all layers of the 
gastrointestinal tract. Mucosal somatostatin is somatostatin-28, while 
somatostatin-14 is of nonmucosal neural origin (71). ie. the somatostatin 
from mucosal endocrine cells and from enteric innervation. In the 
pancreas it is of D-cell origin. Somatostatin containing cells are found 
along the entire length of the gut and in particular at the gastric fundus 
and antrum and in the colon. The somatostatin endocrine cells have an 
apical pole which reaches the lumen and a basal cytoplasmic elongation to 
which a paracrine role is attributed. This elongation lies near to non- 
endocrine cells such as the parietal cells of the fundus or to other 
endocrine cells such as gastrin-containing cells. Somatostatin is known to 
suppress the release of gastrin and gastric add secretion (72).
Somatostatin-containing cells are found by the eighth fetal week in the 
small intestines and stomach (69). In the fetal and neonatal pancreas the
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D-cells constitute up to 25 per cent of the total islet population. In neonates 
with nesidioblastosis(73) the population shows marked depletion even 
lower than in the developed pancreas when it is reduced to around 10 per 
cent.
In the genitourinary system
Somatostatin has been detected both by radioimmunoassay and by 
immunocytochemistry in animals and man. In the human male genital 
tract a few somatostatin immunoreactive nerve fibres have been found in 
the interstitial tissue and amongst the smooth muscles of the prostate 
gland and in the muscular coat of the vas deferens. Interestingly, the 
highest concentrations of somatostatin have been found in the younger 
subjects (rats) of 1.5 and 3 months of age and this concurs with findings in 
humans (60, 74)
In thyroid and thymus
Somatostatin co-exists with calcitonin in the parafollicular C-cells of the 
thyroid and as scattered cells in the thymus. It has been found that the 
number of somatostatin cells decreases with age (75-76). Is this a possible 
factor in the higher occurrence of thyrotoxicosis in adults than in children? 
Somatostatin is known to (a) reduce the synthesis and release of T3 and T4 
stimulated by TSH (77); (b) to inhibit the nocturnal spike of TSH (78); and
(c) to block the TRH-stimulated TSH secretion (79). Relatively high 
juvenile and adolescent thyroid levels of somatostatin may therefore act as 
a protective mechanism against over-stimulation with TSH. It would be 
extremely interesting to study cases of paediatric thyrotoxicosis at least 
some benefit may be obtained from the administration of synthetic 
somatostatin. Its role in the thymus is less clear.
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In other tissues
There is a vast literature on the total body occurrence of somatostatin, 
much of it irrelevant to this present work. Suffice it to say that it is found 
in heart, eye, placenta, and skin. Its presence in the latter suggests a 
sensory role and this fits well with the already mentioned presence of 
somatostatin in the dorsal spinal ganglia. Its presence in some tumour 
tissue is of interest. In pituitary tumours causing acromegaly some contain 
high density somatostatin receptors while others have only low amounts 
of non-homogeneously distributed somatostatin receptors (80-81). This 
correlates well with clinical experience in that some cases of acromegaly 
respond to administered somatostatin while others do not. While 
acromegaly is not a paediatric illness, pituitary gigantism is and this 
information opens up a possible line of treatment for these children. 
However such an exercise would require somatostatin monitoring before 
and during treatment to determine the effective plasma concentration of 
somatostatin in relation to growth restriction.
A further point of developing interest is the fact that when the 
somatostatin analogue (sandostatin) is administered to acromegalic 
patients, the IGF-I plasma concentration is reduced as is also the plasma 
level of growth hormone (82,83).
Mechanism of Action
The action of somatostatin at the various sites of occurrence is uniformly 
that of inhibition. The detail of its action on pituitary derived cells has 
been most studied and it is likely that a similar mechanism may apply in 
all tissues. Somatostatin binds to a specific membrane receptor and 
inhibits adenyl cyclase activity. This it does through coupling with an Ni
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unit which has an opposing effect to growth hormone releasing hormone 
which itself stimulates adenyl cyclase by coupling to an Ns unit.
Somatostatin also has effects independent of its action on cAMP. These 
effects cause a fall in intracellular calcium. This fall reduces growth 
hormone secretion probably via increasing permeability to potassium, 
resulting in membrane hyperpolarization (84).
Physiological action of somatostatin on various tissues
Some of the tissues affected have been mentioned above but a fuller list of 
tissues involved and the net effects of somatostatin is given in Table 1.5 
At this point it is pertinent to say something on the structure of the 
various somatostatins. Most work has been done on somatostatin-14 and 
hence more is known of the action of this compound. Chemically it is a 
sequence of fourteen amino acids as has been seen in Figure 1.2.
Somatostatin-28 is somatostatin-14 N-terminally extended (Fig 1.3) (85). 
There are two other species of 25 and 20 amino acids each containing the 
same COOH terminal 14-amino acid sequence (86). These derive from a 
116 amino acid precursor (87). Most if not all the physiological activity of 
all the somatostatins resides in this COOH terminal 14-amino acid 
sequence i.e. somatostatin-14. Within the molecule it has been found that 
only the amino acid sequence at positions 7, 8 and 9 are absolutely 
necessary for physiological activity, while modifications at positions 6 and 
11 markedly decrease the biological activity. Changes at position 1-5 and 
12-14 do not affect physiological activity (88). Interestingly, substitution of 
the D: isomer at position 8 for the L-trp increases the potency of the 
somatostatin. This increased potency could be due to increased resistance 
to proteolytics. Also, substitution of Phe instead of Lys in the non-essential
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Table 1.5 Inhibitory actions of somatostatin
Tissue Response
1..Anterior pituitary Secretion of GH, TSH and occasionally PRL
and ACTH.
2. Pancreas.(islets)
Secretion of insulin, glucagon and pancreatic 
polypeptide
3. Pancreas exocrine 
(exocrine)
Secretion of water, bicarbonate and enzymes.
4. Stomach. Acid and pepsin secretion and gastric emptying.
5. Intestine. Secretion of fluid and bicarbonate, absorption of
calcium,glucose, fructose, glycerol, xylose, lactose , 
triglycerides, amino acids and mesenteric blood 
flow.
6. Gall bladder. Bile flow.
7. Kidney. Renin secretion, aldosterone response to 
angiotensin II.
8. Parathyroid. Parathyroid hormone secretion.
9. Salivary gland. Salivary flow.
9. Platelets. Aggregation
10. Thyroid Calcitonin secretion.
11. Miscellaneous | Splanchnic blood flow,
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position 4 of somatostatin increases its selectivity for inhibiting growth 
hormone release (89). Deletion of Asn at position 5 increases the relative 
insulin selectivity (90).
The configuration of active somatostatin-14 is like a hairpin, with the 
position held by the disulphide bridge between the cysteine at positions 3 
and 14, with a twin occuring around the tryptophan and lysine at position 
8 and 9. If by reduction the bridge is disrupted, the molecule assumes a 
linear position and is physiologically inactive. Many attempts have been 
made to find a synthetic analogue which would combine increased potency 
with specificity; workers in the Sandoz Swiss Laboratories in Basle by trial 
and error have synthesized an octapeptide (91):
D-Phe-Cys-Phe-D-Trp-Lys-Thr -Cys-Thr-ol
This compound has been found to be twice or thrice as active in inhibiting 
growth hormone secretion by GRF-stimulated pituitary (rat) cells in 
culture. Its increased potency is due to its biological half-life of about 2 
hours compared with the natural hormone of 2 minutes (92). This 
product, known as Sandostatin, is in clinical use for the management of 
acromegaly, thyrotoxicosis and other conditions, as will be seen later. 
Interestingly, several other somatostatin analogues have been shown 
during their experimental trials to have different potency and selectivity 
(93) as shown in Table 1. .
On gastrointestinal system
The greatest contribution of somatostatin to the plasma pool is from the 
gut and related tissues. Somatostatin immunoreactivity is present from 
the oesophagus to the colon. In the stomach, the antral area (D-cells) has
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Table 1.6 Relative potencies of specific somatostatin analogues.
Peptide GH 
(in vitro)
Insulin  
(in vivo)
Glucagon 
(in vivo)
SRIF 100 100 100
DesAsn5-(D-Trp8/ D-Ser^^)- 13 1,750 <1
(D-Trp8, D-Cys14)- 650 130 1,000
(D-Lys4)- 22 <1 <1
DesAsn^^(D-Trp22t D-Ser^?)- 
SS28
<5 14,500 <100
SMS 201-995 300 300 2,300
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high somatostatin-like immunoreactivity, followed by the upper small 
intestines and the D-cells of the pancreatic islets. It inhibits endocrine and 
exocrine secretion, gut mobility, blood flow, absorption, and the growth of 
the gastrointestinal mucosa(Table 1.5). My interest here firstly is concerned 
with its relationship to protein and the absorption of amino acids.
It is recognized that the ingestion of food stimulates the secretion of 
somatostatin into the blood. Fats and protein are potent stimuli of 
somatostatin release, while carbohydrate is rather a poor stimulus (94). 
N onetheless, despite these differences, somatostatin inhibits the 
absorption of glucose, xylose and amino acids(95). Thus, in patients with 
high plasma somatostatin concentrations, caution must be exercised when 
interpreting the significance of the results of glucose and xylose absorption 
tests during the investigation of short statured patients. In these same 
patients some of whom may have low plasma growth hormone 
concentrations either because of an absolute growth hormone deficiency 
state, or because of neurosecretory growth hormone failure, low plasma 
amino acid levels are likely, for one of the actions of growth hormone is to 
increase the nitrogen retention. It follows then that in some children with 
growth hormone deficiency and high concentrations of plasma 
somatostatin, the combined effect will be undoubted low plasma amino 
acid concentrations. This will be explored in this work.
My second interest is in the action of somatostatin in inhibiting gastric 
emptying, gall bladder contraction and slowing of small intestinal transit 
time. It is the experience of many clinical endocrinologists that short 
statured children with and without growth hormone deficiency have 
extremely poor appetite. Could therefore high somatostatin plasma 
concentrations by this acting slow down the total process of eating,
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digestion, absorption and defecation to such a degree that appetite is 
significantly impaired?
Pancreatic tryptic activity is induced by food ingestion. This effect can be 
reduced by the administration of somatostatin. Indeed, it has been shown 
(96) that somatostatin administered reduces the cholecystokinin- 
pancreozymin induced trypsin, chymotrypsin and amylase. But also 
cholecystokinin-pancreozymin secretion itself is inhibited by somatostatin. 
Hence with reduced secretion of trypsin and chymotrypsin it is likely that 
protein digestion and free amino acid absorption are reduced by high 
concentrations of plasma somatostatin. This induced incomplete digestion 
of protein may however lead to an absorption of peptides rather than free 
amino acids.
Finally here, the well recognized high plasma levels of somatostatin found 
in younger children (74) may well be a built-in protective measure against 
overfeeding and gastrointestinal shock from excessive bolus in the upper 
small bowel.
Action on TSH secretion
Interestingly growth hormone and TSH secretion are both stimulated by 
separate releasing hormones, but the secretion of both is inhibited by 
somatostatin(97). Detailed studies of this phenomenon indicate that the 
primary inhibitory effect of somatostatin in vivo is on growth hormone 
secretion, while in vitro its action on the secretion of both growth 
hormone and TSH is equal. Thus an in vivo suppression of TSH is only 
seen when pituitary concentrations of somatostatin are unphysiologically 
high. At thyroid level its presence has already been noted and its action on 
the thyroid to reduce the synthesis and release of T3 and T4. Peripherally
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somatostatin reduces the deiodination of T4 to T3, and increases the 
production of rT3 (77).
On Brain
Most of the research work on somatostatin has utilized somatostatin-14 as 
has been mentioned but interestingly somatostatin-28 exhibits potent 
inhibitory activity on spontaneous GH release which persists for a 
significantly longer period of time than that of somatostatin-14. 
Somatostatin-28 may not therefore be merely a prohormone but a 
regulatory hormone in its own right (98). The biological half-life of each 
respectively is 2.4 minutes and 6.1 minutes.
However, while it is recognized that the pulsatile nature of growth 
hormone secretion as reflected by circadian rhythm is influenced by a 
unique balance between hypothalamic GRF and somatostatin, the 
concentration of the systemic circulating somatostatin also influences the 
basal concentrations of plasma growth hormone. This has been 
demonstrated by infusing rats with somatostatin so as to achieve ultra- 
physiological concentrations, plasma growth hormone diminished sharply 
to almost below detectable levels immediately (99). The interplay of these 
and other growth promoting agents with the hypothalamopituitary axis 
may be summarized by the following schematic drawing (Fig 1.4 shows 
Schematic representation of events leading to control of GH secretion).
Growth hormone is released from the anterior pituitary somatotrophs 
under the influence of GRF. The extent of the release is controlled by 
hypothalamic somatostatin. These hormones have separate receptors (i.e 
acting in a non-competitive fashion) somatostatin binding to Nl receptors 
and GRF binding to Ns receptors on the somatotrophs. The circulating
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growth hormone by passage through the liver and kidneys increases the 
circulating concentration of somatomedin (IGF-I). This in turn acts firstly 
on the somatotrophs to inhibit further growth hormone secretion, but also 
secondarily on the hypothalamus to increase the release of somatostatin 
which in turn suppresses growth hormone release. The growth hormone 
however has a short retrograde loop back to the hypothalamus where it 
inhibits the cells producing GRF. This mechanism integrates 
physiologically the plasma peaks of growth hormone in relation to 
exercise, food and REM sleep. Thus it is now accepted that while diurnal 
inhibition of growth hormone release is likely to be partially under the 
control of systemic somatostatin the necessary plasma peaks are 
neuroregulated by the harmonious integration of growth hormone itself, 
GRF, somatostatin and IGF-I.
Finally to complete this consideration of somatostatin relevant to the 
present work a short reference to insulin and hypoglycaemia is offered. 
Insulin per se stimulates hypothalamic somatostatin release (100), while 
glucose is an inhibitor of hypothalamic somatostatin release. It is therefore 
of interest that peripherally insulin increases plasma somatostatin 
indirectly through its hypoglycaemic action, for in hypoglycaemic states 
somatostatin is increased. The relevance of this to our subject is that 
patients with growth hormone deficiency lack GH-anatagonism to insulin 
and are therefore likely to experience plasma glucose concentrations in the 
lower normal range. It could be that thereby there is an added tendency to 
increased plasma somatostatin concentrations. In persistently low plasma 
glucose states, glucagon secretion increases as part of the glycaemic 
restorative mechanism. Again glucagon stimulates D-cell somatostatin 
secretion. Thus several mechanisms may be at work to raise the plasma
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Figure 1A Main influences in  the control 
of growth horm one secretion.
somatostatin concentrations in the GH-deficient patients which I shall 
present in this work.
Clinical Uses of Somatostatin
Because of the various modes and sites of action of somatostatin, it is not 
surprising that it has been experimentally used in many conditions. The 
formulation of the more potent octapeptides with somatostatin activity 
has emboldened clinicians to therapeutic endeavour. Table 1.7 gives a list 
of conditions in which somatostatin has had clinical and therapeutic 
trials.
At our level of interest, somatostatin may have a role investigatively and 
therapeutically. Firstly, the interesting work (99), in which infusion of 
somatostatin leads to an immediate fall in plasma growth hormone 
concentrations which were followed by rebound peaks of growth hormone 
on sudden withdrawal of the infused somatostatin, suggests that such a 
principle could form the basis for a research tool to determine the status of 
GRF in short statured patients. The procedure could readily be combined 
with a lh  GRF test and so only two samples of blood, one for each test, 
would be necessary to determine the pituitary synthetic capacity for growth 
hormone and the hypothalamic status of GRF.
Secondly, because of its action in suppressing insulin secretion it may have 
a place in the seldom occurring cases of nesidioblastosis. But its 
therapeutic actions would require close monitoring of the plasma 
somatostatin concentrations achieved, for in the final analysis its role can 
only be symptomatic and not curative. In Type I diabetes somatostatin 
also has a role -  here because of its suppressing action on growth hormone 
and glucagon release to reduce nocturnal hyperglycaemia. While insulin
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replacement will always be required, also in Type I diabetic patients, the 
insulin dosage requirement may be reduced and the course of the brittle 
diabetic smoothed if somatostatin can be found to be a suitable adjuvant to 
treatment. Additional support for the concept involving growth 
hormone suppression comes from the link between growth hormone and 
microvascular complications in diabetic patients since it has been found 
that growth hormone-deficient dwarfs with diabetes usually lack 
microvascular complications (101) and, more interestingly(102) was the 
diabetic retinopathy produced in dogs as a result of growth hormone 
injection.
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Table 1.7 Clinical uses of somatostatin.
1. Central neuroendocrine disorders.
Acromegaly.
Excessive TSH secretion.
Defective ACTH feedback (Addisson, Nelson.)
2. GIT tumours and related conditions.
Insulinoma.
Nesidioblastosis
Vipoma.
Glucagonoma
Gastrinoma.
Carcinoid.
3. Non-tumoural GI conditions.
Malignant diarrhoea 
Pancreatic fistula and pancreatitis. 
GI bleeding.
4. Diabetes. Type I (insulinopenic)
Type II (peripheral resistance)
5. Blood pressure regulation.
Hyperreninaemia.
Aldosteronism.
6. Tissue growth inhibition.
Skin (EGF ?)
Malignant tissue.
7. Cytoprotective.
8. Miscellaneous.
Burns, trauma, sepsis.
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Amino Acids
Protein (Gr; proteois) was early recognized as necessary for life in a more 
fundamental way than carbohydrates or fats. Protein destruction in the 
body was observed to result in increased urinary nitrogen so that the 
estimation of urinary nitrogen became a measure of protein turnover. 
The smallest unit of the protein is the amino acid. Glycine was the first 
amino acid to be isolated; gelatine was the source material.
Tryptophan was found to be required preformed in the diet of rodents (103) 
and it was confirmed later that lysine and sulphur-containing amino acids 
were nutritionally essential(104). The last nutritionally essential amino 
acid to be recognized was threonine (105).
All amino acids contain at least one amino group (-NH2) in the a-position  
and a carboxyl group. The simplest structure of an amino acid then is 
glycine as under.
H
I
R —  C —  COOH 
I
NH2
All amino acids contain an asymmetric carbon atom, except glycine .
Most amino acids contained in protein are in the laevo form, in which 
they are important in human metabolism. D-forms occur mainly in 
micro-organisms. D-amino acids are poorly absorbed and rapidly excreted. 
The common amino acids are listed according to their chemical structure 
and property in Table 1.8.
The terms glucogenic and ketogenic amino acids are now obsolete, but they
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T a b l e  1.8 Pro te inder ived  L-amino acid s t r u c t u r e  and t h e i r  chemical  
ch a ra c te r i s t i c s .
Ami no acid 
qroup
Trivia l
name
Symbol Chemical
c h a ra c te r i s t i c s
S t ruc tu ra l  fo rmula
N eutral Glycine Gly „ S tra ig h t chain H-CH-COOH■
amino acids 1NH2
Alanine Ala =  = CH3-CH-C00H
1
NH2
Leucine Leu Branched ’R‘ CH3s.^CH-CH~-CH-COOH
C H 3 ^  2  1
NH2
Isoleucine
Valine
lie
Val
= =
CH3 " CH?.
^CH-CH-COOH 
H3 C /  1 
5  NH2
H3 c  v
CH-CH-COOH 
/  I 
H3C NH2
S erine S e r OH-containing’,R'
CH--CH-COOH 
1 2  1
OH NH2
Threonine Thr = =
CH3  -CH-CH-COOH
1 1
OH NH2
C ysteine Cys SH-containing*'R' CH3 -CHo-CH-COOH 
1 2  1 
SH NH2
Methionine Met = = CH?-CHo-CH-COOH 
1 2  2 1 
S -CH 3  NH2
Continue
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Continue
A m ino ac id  
groups
T r iv ia l
n am e
Symbol Chemical
cha ra c te r i s t i c s
S t ruc tu ra l  fo rmula
Neutral 
ami no acid3 Pro l ine Pro Imi no acid
^ n ^ c o o h
OH-prol ine Hyp = =
H 0  «
COOH
Phenylalanine Phe Aromat ic ,,R“
1
H
/ " ~ V -  C H 2 -C H -C O O H  
N H 2
Tyrosi ne T y r H 0  V -  C H 2 -C H -C O O H  
N H 2
Tryptophan Trp t  U ^ / ^ H 2 ‘C H "C 0 0 H
N H 2
H
Aspargi ne Asn Amides co ta i -  
n in g ’FT
H 2N -C —C H 2 -C H -C O O H  
II i 
0  N H 2
GI utamine Gin =  sr H 2N -C — C H 2 —C H 2 -C H -C O O H  
II i 
0  N H 2
Acidic Aspart ic  acid Asp (COOH)-Contai­ H O O C —  C H 2 -C H -C O O H
amino
acids GI utamic acid Glu
n in g " ^ ' N H 2
H O O C -C H 2  —C H 2 -C H -C O O H  
N H 2
Basic 
ami no 
acids
Argi ni ne 
Lysine
Arg
Lys
NH2-contai -  
ning "R"
H -N -C H 2  -  CH 2 -C H 2 -C H -C O O H  
C = N H  N H 2  
N H 2
C H 2-C H 2-C H 2-C H 2-CH -C 00H
ISIH2 NH2
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serve to indicate their behaviour in vivo. For instance, the glucogenic 
amino acids are capable of stimulating insulin secretion, presumably to 
deal with the increase in blood sugar derived from their utilization. 
Phenylalanine, tyrosine, leucine and isoleucine are degraded in part to 
acetoacetate, whereas other amino acids are degraded chiefly to pyruvate, 
oxaloacetate, a-ketoglutarate, succinate and fumarate. The metabolic fate 
of the amino adds indicates whether they are glucogenic or ketogenic .
The former nomenclature of essential and nonessential amino acids has 
given place to two new terms, namely indispensable amino acids (IDAA's) 
and dispensable amino acids (DAA's) (106). In terms of the nutritional 
value of amino acids, it is important to note that a few amino acids do not 
fit into either category. Some of these amino adds such as arginine, which 
although synthesized by the body are not synthesized in sufficient 
amounts required for the physiological needs of the young rapidly growing 
subject. Cysteine and tyrosine synthesized only from methionine and 
phenylalanine respectively are indispensable amino acids if their 
precursors are not present in a diet in adequate amounts or if there is a 
defect in the pathway by which they are synthesized. Such a situation has 
been found in the absence of cystathionase activity (the enzyme which 
cleaves cystathionine to cysteine) in fetal liver and brain. Cystathionase in 
low activity has also been found in premature infants and in full term 
infants who died immediately after birth (107). This observation has been 
confirmed by the fact that cystathionase activity is significantly correlated 
with gestational age and increases rapidly after birth (108), Such amino 
acids as cysteine are termed semi-indispensable or even more suitable 
conditionally indispensable. A classification of amino acids according to 
their nutritional function and metabolic fate is shown in Table. 1.9
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Table 1.9 classification of amino acids according to their functional and 
metabolic fate.
Nutritional function Metabolic fate
Indispensable Dispensable *Cond.indisp Glucogenic Ketogenic Gluco-Keto
Valine Alanine Cysteine Alanine Leucine Isoleucine
Leucine Glycine Tyrosine Glycine Lysine
Isoleucine Serine Arginine Serine Phenylala­
nine
Threonine Cysteine Histidine Histidine Tyrosine
M ethionine Proline Proline Tryptophan
Phenylalanine OH-proline OH-proline
Tryptophan Asparagine Asparagine
Lysine Aspartic
acid
Aspartate
Glutamine Cysteine
Glutamic acid Glutamate
Methionine
Threonine
Valine
* conditionally indispensable.
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When young animals are fed a diet containing a high proportion of 
indispensable amino acids, the dispensable amino acids synthesized from 
these are slow to reach optimum levels necessary for maximum growth. 
Thus the dispensable amino nitrogen can become a limiting factor for 
growth in the human infant who is on a low intake of high quality protein 
or who, from this thesis's point of view, may lack a stimulus for the 
utilization of nitrogen from DAA's or IDAA's. An important point is that 
the IDAA's other than lysine and threonine can be replaced in diets by 
their a-keto analogues. Lysine and threonine therefore may be the only 
amino acids which are truly nutritionally indispensable, since they do not 
pass through an a-keto stage in their resynthesis.
The IDAA's must be ingested. On the other hand in normal man during a 
24-hour period almost about 16 g protein from the digestive enzymes are 
found in the lumen of the gut, 50 g from the shed cells from the intestinal 
mucosa and 6  g from the serum albumen, these latter are actively secreted 
into the intestinal lumen. From this protein pool some indispensable 
amino acids must result so contributing to that ingested in the diet. 
Dietary protein will therefore cause a fluctuation of the plasma 
concentrations of amino acids, but the endogenous supply as above will 
maintain an evenness of plasma amino acids throughout the 24-hour 
period. (109)
Valine, leucine and isoleucine (branched chain amino acids)
These amino acids are of particular interest in that they are the only amino 
acids which are only partially degraded in the liver. After a meal rich in 
protein the effusion of blood to the systemic circulation contains a higher 
percentage of these branched chain amino acids than was contained in the
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protein of the meal. The excess of the other amino acids (both 
indispensable and dispensable ) are selectively degraded by the liver so 
that more than 70 per cent of the increase in free amino nitrogen leaving 
the liver after a meal is accounted for by the branched chain amino acids 
while only some 20  per cent of these amino adds are contained in the meal 
(110). The circulating branched chain amino acids are transaminated and 
degraded peripherally in muscle, kidney, adipose tissue and brain. Apart 
from their role in protein synthesis, it is this peripheral catabolic process 
which makes them energy-yielding substrates. They are deaminated in 
muscles especially during fasting to their oxo-acids which in turn are 
utilized in the liver as glucogenic or ketogenic substrates. Following a 24-h 
starvation there is a considerable increase in these amino adds while the 
concentration of some other amino acids falls. Leucine also acts as a 
regulator of protein turnover. Low concentrations of leucine stimulate 
protein synthesis while high physiological levels inhibit catabolism of 
tissue protein (111).
There is one aminotransferase acting on all these branched chain amino 
acids converting them to their corresponding oxo-acids. A very specific 
leucine aminotransferase does exist in some tissues. The catabolic 
aminotransferase is found mainly in skeletal musde and after cleavage of 
the amino group alanine is formed which is exported to the liver as a 
glucogenic substrate (112).
The importance of these facts to the present work is that growth hormone 
in its protein synthesizing role will facilitate and perhaps accelerate the 
incorporation of these branched chain amino acids into muscle to increase 
the mass of muscle protein and probably also facilitate the increase in 
muscle length (commensurate with increase in bone length). Also leucine
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reduces the rate of protein catabolism. The high concentration of leucine 
in maple syrup disease inhibits muscle protein catabolism and so reduces 
the availability of alanine as a glucogenic amino acid. Hence the frequent 
attacks of hypoglycaemia in this disease of branched chain amino acid 
metabolism (109).
Lysine and Threonine
It has already been stated that these are the two truly indispensable amino 
acids because they cannot be generated from their a-keto-forms. They are 
required for muscle protein synthesis and hence their prime importance as 
dietary constituents and subsequent absorption.
Threonine has an hydroxyl side chain and because of this contributes to 
the hydrophilicity of proteins. This hydroxyl group is readily available for 
phosphorylation catalysed by protein kinases. Thus such catabolism is a 
means of exporting phosphate e.g. casein which is heavily phosphorylated 
and provides most of the phosphate required for bone mineralization in 
the growing child (113). Thus in the absence of an adequate intake of 
casein, threonine in a small way may compensate as a phosphate donor. 
Adequate plasma concentrations of this amino acid are therefore desirable. 
However on an average dietary protein intake there is a relatively narrow 
range of threonine content and high threonine foods such as eggs and 
meat are required to provide recommended daily requirements of 
threonine i.e.40 mg /k g  /day. On the other hand L-lysine is catabolised 
into a-aminoadipic acid and to piperidine carboxylate. Failure of this 
pathway results in hyperlysaemia with an accumulation of saccharopine. 
While threonine is catabolised into an a-ketobutyrate which in turn is 
oxidatively decarboxylated to yield proponyl CoA. This latter will then 
enters the Krebs cycle through certain chemical reactions .
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Alanine, Glycine, Serine and Tyrosine
We have already noted that alanine is derived from the branched chain 
amino acid catabolism in muscles and is transported to the liver as a 
glucogenic amino add. Additionally alanine is formed in the mucosal cells 
of the gut from glutamic add and glutamine and transported via the portal 
vein to the liver for gluconeogenesis (114).
Glycine has serine as its precursor. It can also be derived from glyoxalate 
derived from any other source. In catabolism it may also condense with 
another molecule of glycine to form serine. Serine synthesis occurs 
through the pentose phosphate pathway, from glycine cleavage. Metabolic 
fate of serine is to pyruvate.
Tyrosine which is considered to be conditionally indispensable amino acid 
is derived from phenylalanine. In catabolism it is deaminated through 
homogentisic add to acetoacetate and fumarate.
In Figure 1.5 are shown the various pathways by which the carbon 
containing chains and the amino groups are separated. The mechanisms 
of this separation are transaminations or oxidative deaminations. The 
disposition of the carbon chains is the factor determining the formation of 
either ketone bodies or glycogen. The portions of the amino acids which 
form Krebs cycle intermediates are glucogenic, i.e. forming glucose 
through oxaloacetate and phosphoenolpyruvate. The ketogenic portions 
give rise either to acetoacetate or acetyl CoA. Whether glucogenic or 
ketogenic, the importance is that either substance can be quickly mobilized 
for energy production.
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Figure 1.5 Metabolic fates of carbon skeleton of amino acids.
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/Protein as source of amino acids
Dietary protein is the principal source of amino acids although we have 
seen that there is a component from proteinous secretion into the gut. 
Proteolytic enzymes break down the proteins to amino acids and peptides 
in the gastrointestinal tract. But some small proteins and peptides are 
absorbed from the intestines. Amino acids are the main and smallest 
fractions of protein digestion. They circulate in the blood and may be 
measured as plasma amino nitrogen or as individual amino acids.
Digestion commences in the stomach where pepsinogen from the chief 
cells in the mucosa is converted to pepsin which then proceeds to break 
down the protein to polypeptides (115). The peptide gastrin from the 
distal end of the stomach actually triggers the chief cells to produce 
pepsinogen. Similarly the pancreas releases its digestive juice stimulated 
by secretin a hormone of the duodenum stimulated by the presence of acid 
gastric chyme in the duodenum. The acid gastric chyme is then 
alkalinized by bile from the liver and bicarbonate from the pancreas. Also 
from the pancreas comes chymotrypsinogen, trypsinogen, proelastase and 
procarboxy-peptidase. Trypsin, chymotrypsin and elastase are endo- 
peptidases, they cleave proteins and polypeptides at internal sites, usually 
at specific amino acid residues (116). Garboxypeptidases (A and B) are 
exopeptidases cleaving amino acids from the carboxyl ends of polypeptide 
chains. The resulting proteolytic enzymes have remarkable specificities for 
cleaving protein chains at certain amino acid residues. The products of 
these enzymes are free amino acids, dipeptides and small peptides. The 
residual peptides are hydrolyzed in the intestinal mucosal cells by 
aminopeptidases and dipeptidases.
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Absorption of Amino Acids
A substantial amount of small peptides as well as amino acids are absorbed 
by stereospedfic systems. Mainly amino acids are found in the portal blood, 
peptides being hydrolyzed by peptidases in the absorptive cells.
Amino Acid Transport System
The absorption of neutral and basic amino acids is mediated by separate 
carrier systems. In Hartnup disease neutral amino acids are not absorbed, 
although the basic amino acids are adequately absorbed (117). The reverse 
is true in patients with cystinuria.
The intestinal absorption of L-amino acids is much faster than for the 
corresponding D-isomers. Indeed D-amino acids may not be actively 
transported, although at a much reduced affinity D-amino acids share in 
the L-amino acid carrier system (118).
Amino acids with a long side chain have a greater affinity for the transport 
system than do those with a short side chain (119). The importance of this 
is the selective rate of absorption of amino acids containing equivalent 
amounts of either eight indispensable or the eighteen common dietary 
amino acids.
Absorption of amino acids is not affected within a wide range of changes 
in the intraluminal concentration of sodium, nor by the pH (120) . Neutral 
amino acids are more rapidly absorbed from the distal jejunum than from 
the proximal jejunum, and certainly more rapidly than from the distal 
ileum. Recently active transport of neutral amino acids was demonstrated 
in the duodenum and is described as being an active sodium dependent 
mechanism (121 ). Amino acid absorption seems to be reduced by
starvation, although starvation does not alter the selectivity for 
absorption(122).
Although these facts have been well established during the past two 
decades, there is a current volume of literature on this subject using more 
modern techniques involving human intestinal brush-border membrane 
vesicles experiments. These works confirm the presence of different 
systems for amino acid transport and they even have shown that for the 
transport of the acidic amino acids there is an apparently electroneutral 
manner which utilizes an inward sodium gradient and an outward 
potassium gradient( 123, 124).
Peptide transport system
Dipeptides and tripeptides are also absorbed by the human intestine. 
Neutral, basic and acidic dipeptides share a common mediated mechanism 
for transport (125) which is a non-concentrative, Na+ independent, carrier 
mediated system There is also here a preference for L-peptides with short 
chain N-terminal amino acids in the absorption system and lowering of 
the intraluminal pH results in a less restricted absorption of peptides than 
of amino acids. Absorption of peptides in man is maximal in the 
jejunum, minimal in the duodenum and intermediate in the ileal region, 
where hydrolysis of peptides exceeds that of the jejunum (126).
Interestingly, in coeliac disease free amino acid absorption is more 
impaired than is that for peptides and this even in the face of villous 
atrophy and hence loss of brush border. It may well be that in this disease 
ileal absorption, with its greater hydrolytic capacity, compensates for loss 
due to the jejunal pathology.
Amino acid imbalance and antagonism
Body mechanisms in health are geared to handle a balanced intake of 
amino acids as they are represented in dietary protein. A relatively large 
excess of any one essential amino acid administered along with a protein 
reduces the biological value of the protein and especially when the excess 
of the amino acid is gross and the protein intake marginally adequate. 
This situation is said to depress growth (127). Differences in the 
concentration of the essential amino acid versus the adequacy of the 
protein diet determines the degree of growth restriction.
When the total intake of protein is increased to slightly above the 
minimum requirement, the addition of the excess amino acid has no effect 
on growth (128). Thus in humans, eating more protein than the 
minimum amount of protein required imbalances of any single or 
combined indispensable amino adds are unlikely to have any detrimental 
effect. From these data it is clear that when treating protein malnourished 
children, dietary protein increase is much to be preferred to an increased 
intake of isolated indispensable amino adds.
Interestingly, there is an antagonism between some amino adds when one 
is present in relative excess. For example, the addition of an excess of 
arginine to a diet reduces the biological value of proteins that are not 
limited by lysine, yet only the addition of lysine will restore nitrogen 
balance. Similarly the branched chain amino acids are mutually 
antagonistic -  excess of leucine impairs utilization of dietary protein and 
only the addition of isoleucine and valine will overcome the effect. In 
infants after an overnight fast, the concentration of threonine in the 
plasma shows an inverse relationship with dietary lysine (129),whereas in 
young adults such a reciprocal relationship does not obtain (130).
Free Amino Acids in Plasma
The level of plasma amino acids is related to their quantity in food 
proteins, although the true nature of the relationship is one of complexity. 
Nonetheless the plasma amino acid levels reflect a state of equilibrium -  a 
balance between the entry of amino acids into the circulating pool and 
their removal by various tissues.
In the pool the amino acids are in the free state. It cannot yet with 
certainty be stated which portion of the amino acids removed from the 
pool will be used for protein synthesis and which for combustion, so that 
the relationship between dietary and plasma amino acids is of very 
doubtful significance. At most the pattern of resorbed and free plasma 
amino acids will correspond when dietary proteins have a relatively high 
biological value. This fact has given rise to the study of plasma amino acid 
ratios, especially indispensable to dispensable amino acids. Changes in this 
ratio depend on the nature of the protein ingested, and the subsequent 
effects on the dispensable amino acids. In other words, restriction in 
protein ingestion and absorption alter the nutritional ratio by increasing 
the dispensable amino acids, thus lowering the ratio, while correction of 
the ratio can be achieved by increasing the quantity of protein ingested.
Clinical importance of amino acids
We have already considered the glucogenic and ketogenic actions of amino 
acids. As precursors in metabolic pathways they are important. For 
example, tyrosine from phenylalanine is necessary for thyroxine synthesis. 
Sulphur containing amino acids give rise to taurine. Glycine contributes 
to the porphyrin ring of haemoglobin and with serine provides part of the 
structure of purines and pyrimidines of the nucleic acids. Glycine is also a 
constituent of glutathione. It also conjugates with cholic acid to form bile,
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and with benzoic acid to form hippuric acid which is used in liver function 
tests. Amino acids are indispensable also for the formation of enzymes 
and hormone. In screening for inherited disease, specific amino acids are 
identified. For example, in phenylketonuria, phenylalanine blood 
concentrations are estimated. This is the basis for the Guthrie test, and 
facilitates early detection and treatment of that disease.
Therapeutically, amino acids have special value such as in chronic liver 
disease with encephalopathy. Because the branched chain amino acids are 
not metabolized by the liver, they may be given by infusion as a source of 
energy for extrahepatic metabolism. Also a second benefit from an 
infusion of the branched chain amino acids is that there will be a 
restriction of the aromatic amino acids which in turn spares the 
production of serotonin and noradrenalin both of which increase 
drowsiness in case of hepatic encephalopathy.
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The Rationale
The reader might be justified in wondering what is the relationship 
between growth hormone, amino acids and somatostatin. Throughout 
this introductory chapter I have here and there hinted that there is or may 
be indeed a relationship which when applied to children with growth 
hormone deficiency, would offer an explanation for their response to 
administered growth hormone.
Basic to the theory to be tested is firstly the fact, generally accepted that 
growth hormone in one of its actions raises the concentration of plasma 
amino acids. This of course is logical if perhaps firstly physiological for if a 
child is to grow then all the growing structures, cartilage, bone, muscles 
and organs require protein, the building bricks of which are amino acids. 
That is easily understood and accepted.
Secondly, it is now well accepted that somatostatin is uniformly an 
inhibitory substance and in the context of this work it inhibits the release 
of preformed growth hormone from the pituitary and it also inhibits the 
absorption of amino acids. This really is a nett effect for in so doing it 
inhibits gastric and gut motility, it inhibits digestive enzymes and it 
inhibits the transport of intraluminal contents through the gut wall ie. 
absorption. Thus by preventing adequate plasma concentrations of both 
growth hormone and amino acids , it is in effect an inhibitor of linear 
growth.
But it might be argued that it is the hypothalamic somatostatin which 
inhibits the release of growth hormone, reaching the pituitary via the 
axons of the cells which synthesize it and along with GRF is taken to the 
eosinophils of the anterior pituitary by the long and short pituitary portal
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vessels. Why then do I study plasma somatostatin concentrations ? For 
this reason - the long and the short pituitary portal vessels are the 
channels by which the pituitary receives its blood supply, and these vessels 
are twigs from the superior and inferior hypophyseal arteries. Thus the 
anterior pituitary is constantly being bathed with systemic blood 
containing a measurable concentration of somatostatin. My hypothesis is 
therefore that hour by hour the pituitary is under the tonic control of 
plasma somatostatin by way of controlling the release of growth hormone 
and only in response to the spikes of GRF associated with food, exercise 
and REM sleep, does the hypothalamic somatostatin buffer the possible 
gross fluctuations of growth hormone release. Thus high plasma 
concentrations of somatostatin may therefore not only depress the release 
of growth hormone but may also lower the concentrations of plasma 
amino acids, setting the stage for possible short stature.
At the clinical level it is well recognized that some children make more 
gains in linear growth than others who are treated similarly with growth 
hormone. The interesting point then is that could it be that those children 
who do not respond to growth hormone therapy as might be expected, 
have unduly, or pathologically high plasma concentrations of 
somatostatin ? Were this to be so, the question arises as to the reason for 
the increased concentrations of plasma somatostatin, Are we here dealing 
with a two-way inseparable relationship between plasma somatostatin and 
amino acids, viz when plasma somatostatin concentrations are high, are 
the plasma concentrations of amino acids low and vice versa? There is one 
point which might support such a view namely that infused arginine and 
other amino acids result in a rise in plasma growth hormone concen­
trations. Could it be that the growth hormone is released because the 
inhibiting somatostatin concentration has been lowered thereby? And
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reciprocally does administered growth hormone raise the plasma 
concentrations of amino acids? thereby lowering the plasma concentration 
of somatostatin - thereby normalizing the high plasma somatostatin 
values.
While in the patients to be studied here all have growth hormone 
deficiency, the data to be derived may have some application to children 
with short stature not due to growth hormone deficiency. In other words, 
could non-growth hormone deficient short stature in otherwise normal 
children be due to either high plasma concentrations of somatostatin, or to 
low plasma concentrations of amino acids or a combination of both?
To what extent the study to be presented here will answer these questions 
and justify the thesis will unfold as the data are presented in the following 
chapters.
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CHAPTER TWO.
Materials and Methods.
It is seldom that medical catastrophes can be utilized to the advantage of 
scientific research but such has been the outcome of the scare of 
Creutzfeldt-Jacob disease as a possible illness following cadaveric growth 
hormone administration. In the Spring of 1985 following reports of 
Creutzfeldt-Jacob disease occurring in patients who had received human 
growth hormone (14. 15), the drug was withdrawn from the 32 patients of 
this thesis who were then attending the Growth Clinic of the Royal 
Hospital for Sick Children, Yorkhill, Glasgow. At that time blood was 
taken from each patient so that the virus or an antiviral titre could be 
studied in each sample. The plasma samples were stored at -20°C.
About the same time increasing awareness was developing regarding the 
acquired immune deficiency syndrome and while little was known of the 
neurotrophic nature of that virus, it seemed reasonable against possible 
claims to preserve plasma samples for the future.
Fortunately from the date of withdrawal of cadaveric growth hormone as 
therapy to the becoming available of recombinant growth hormone only 
nine months elapsed so that most patients recommenced growth 
hormone therapy within the nine month period.
Almost concurrent with the announcing of the Creutzfeldt-Jacob scare I 
arrived in the Department of Child Health to commence studies which 
would be suitable for a Ph.D., degree. My attention was therefore drawn to 
the study of the effects of growth hormone withdrawal and its 
recommencement in terms of growth and some plasma biochemical
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changes relative to plasma somatostatin and plasma amino acid 
concentrations.
Clinical Material
The cohort of patients studied consisted of 21 boys and 11 girls whose ages 
ranged from 2.17-17.94 years. These children had been diagnosed as 
having growth hormone deficiency and all had been accepted by the 
Health Services Human Growth Hormone Committee as suitable for 
growth hormone therapy. Anthropometric data were taken for each child 
at the time of withdrawal of cadaveric growth hormone, at the occasion of 
recommencement of recombinant growth hormone and one year later. 
These data will be presented in Chapter 3. The fluctuations in height and 
osseous maturation scoring will also be shown in Chapter 3.
Care was made to obtain an accurate standing height estimations during 
this work by using apparatus supplied by Raven Equipment Ltd., 
Dunmow, Essex (Figure 2.1 A)
In general to ensure reliable and accurate height measurement, 
irrespective of the apparatus used, the position of the child is crucial; poor 
positioning results in inaccurate measurement, thus:-
a. The shoes and the socks should be removed, and the feet should be 
together and flat on the platform with the heels touching the backboard.
b. The legs should be straight with the buttocks and the scapulae against 
the backboard.
c. The head should be positioned carefully with the lower orbital margins 
in the same horizontal plane as the external auditory meati. Sufficient
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downward pressure should be exerted to compress the hair. The mean of 
three readings was obtained for accuracy.
Actual heights were converted to standard deviation scores as generally 
accepted in paediatric practice (1). Indeed I have expressed plasma 
concentrations of somatostatin and amino acids also as standard deviation 
scores. Since standard deviation scores relate an observation to the 50th. 
centile, the age factor is accounted for in the calculation. To obtain the 
50th centile values for the patients in my cohort particularly for plasma 
somatostatin and amino acid concentrations it was necessary to extend the 
range of those normal values which were already available in the 
Laboratories of the Department of Child Health by adding to them data 
personally derived from an older age group of normal subjects (Appendix 
Table 1&2). From the combined data I will show in Chapter3 some 
examples of the regression analyses for both plasma somatostatin and 
amino acid concentrations in relation to the chronological age.
Biological Sample Collection and Storage
Venous blood (10ml) was collected from a suitable vein following an 
overnight fast. An aliquot (5ml) for plasma somatostatin assay was placed 
in a chilled test tube (10ml) containing 7.2 mg. EDTA and Trasylol 
(Aprotinin) 500 KIU. The remaining blood was heparinized, the plasma 
separated and stored at -20°C against amino acid assay. The blood for 
somatostatin assay was immediately extracted and the extract freeze-dried 
and stored at -20°C against final assay.
Laboratory Material
Chemicals: Acetic acid, acetone, acetyl chloride, ammonia solution, n- 
butanol, ethyl acetate, chloroform, dichloromethane, isobutylalcohol,
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hydrochloric acid, methanol, petroleum ether and sodium hydroxide 
solution were purchased from British Drug Houses Limited (BDH), Poole, 
Dorset, U.K. All were of Analar grade .
Toluene (Scintillation Grade) was purchased from BDH Ltd. Both PPO (2:5- 
diphenyloxazol and POPOP (l,4-di-(2-(5-phenyl-oxozalyl)-benzene)] were 
purchased from Hopkins and Williams Ltd., Reading Industrial Estate, 
Falkirk.
Heptafluorobutyric anhydride was purchased from Koch-Light Labora­
tories Ltd., Colnbrook, Buckinghamshire, U.K.
Crystalline amino acids were bought from Sigma, Fancy Road, Poole, 
Dorset. Also Sigma supplied an amino acid calibration standard solution 
(2.5 umol per ml in 5ml 0.05 M HC1.) and an ion-exchange resin (Dowex- 
50 W 8  percent cross link, 200-400 dry mesh).
Ninhydrin spray (0.5 percent in n-butanol ) was purchased from BDH 
Chemicals Ltd.
14C-labelled amino acids valine, leucine, isoleucine and cycloleucine (SA 
50 mCi per mmol) were purchased from Amersham International PLC., 
Buckinghamshire, England, in 2  percent ethanol/water solution(lm l) 
(50uCi per ml).
Gases. Nitrogen (oxygen-free), oxygen and Argon/Propane (98 percent/2 
percent) were obtained from BOC Ltd., Polmadie Avenue, Glasgow.
Equipment.
Gas liquid chromatography apparatus (Figure 2.1 B). A Pye Unicam Series 
304 (Pye Unicam, Cambridge, U.K.) equipped with dual column oven,
85
flame ionizing detectors and a built in temperature programmer was used. 
A computing integrator (COPI) which gave prints out of retention times 
and either peak height or peak area was attached. A single pen recorder 
(Phillips) and standard chart paper (PM 9920/00) was used for trace 
recording.
Liquid Scintillation Counter. The radioactivity of the standards for initial
and recovery experiments was measured by a liquid scintillation
spectrophotometer (Pye Unicam LSC, York Street, Cambridge, U.K.). The
14 3instrument was calibrated for simultaneous counting of C and H.
Radiochromatogram Scanner. A Panax thin layer Radiochromatogram 
Scanner Model RTLS (Panax ESI, Rotheroe and Mitchell, Redhill, Surrey, 
U.K.) in conjunction with a flat bed recorder (Smiths Industries Ltd., 
Industrial Instrument Division, Kelvin House, Wembly Park, Middlesex) 
was used for the identifying the loci of the radioactively labelled amino 
acids on TLC plates. The detector carrier gas was a mixture of argon (98 
percent) and propane (29 percent) and the flow rate was set at 50 ml per 
minute. The Geiger Muller detector voltage was set at 1,040 V: the detector 
dead time at 200 msec, and the discriminator bias at 10 mV. A time 
constant of 100 seconds and a scanning speed of 30 mm per hour were 
used. The detector was adjusted to a height of approximately 1 mm above 
the thin layer plate and all plates were scanned using the 15 x 1 mm 
detector aperture. The range of peak heights varied with the amounts of 
radioactivity in the areas of the test sample.
Gamma Counter. A Panax Autobioscint Counter (ESI Panax, Rotheroe 
and Mitchell Ltd, Ruislip, Middlesex, England) was used for measuring the 
radioactivity in plasma samples assayed for somatostatin (125I).
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Figure 2.1 A.Karimeter
B. Gas Liquid Chromatography
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Freeze Drier. A freeze drying machine, Edwards High Vacuum 9 
(subsidiary of BOC Ltd, Manor Royal, Crawley, Sussex, England.) was used 
for sample drying.
Water Deionization Apparatus. An ELGA Spectrum (System D. SCI) with 
mixed bed deionization cartridge (ELGA Products Ltd. Lane End, 
Buckinghamshire, England ) was employed for water deionization.
Refrigerated Centrifuge. A Supermagnum refrigerated centrifuge (MSE, 
Manor Royal, Crawley, Sussex, England) was used for sample 
centrifugation during somatostatin assay.
Thermostatically controlled Oven. A Gallenkamp Super Hot Spot Furnace 
(FR 520) was obtained from Gallenkamp Co. Ltd., Sun Street, London, 
England.
Glassware. Glass vacuum thimbles were purchased from McQuilkin and 
Co., 21 Polmadie Avenue, Glasgow. These thimbles consist of a scintered 
glass filter disc incorporated into a tube of glass with expanded walls at 
either side of the scintered filter. These were used during the elution of 
samples of amino acids from silica. A Pyrex glass column (3m x 6.35mm 
OD, 2mm ID) was obtained from Phase Separation LTD., and was used in 
the Gas Liquid Chromatography Unit.
SGE syringes (5ul and lOul ) were obtained from Scientific Glass 
Engineering (U.K.) Ltd., Potters Lane, Kiln Farm, Milton Keynes, U.K.
Sealable Glass Ampoules (1 0ml) were obtained from Adelphi 
Manufacturers Co. Ltd., Duncan Terrace, London, U.K. Trident Vials were 
bought from Scientific Supplies, Scientific House, Vine Hill, London, U.K. 
Graduated pipettes and Pasteur pipettes were purchased from Macfarlane
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Robinson Ltd., Hedgefield House, Blavddon-on-Tyne, Tyne and Weir, 
U.K.
Preparation Procedures 
Preparation of Working Solutions
Acetic acid (5M) was prepared by adding glacial acetic acid (1.049 g. per 
ml)(286 ml) to deionized water (714 ml). The solution was stored in a glass 
bottle with a glass stopper.
Ammonium hydroxide (2M) was prepared from ammonia solution 
(Analar Grade) (SG 0.88) by adding 112ml to deionized water (888ml). The 
solution was stored in a glass bottle.
Esterifying agent was prepared as described (132) by adding acetyl chloride 
(275 ul) dropwise to isobutanol (1ml) at °C in a dry glass tube supported in 
an ice bath.
Hydrochloric acid. (1.0 and 5.0 molar solutions were prepared from 
concentrated hydrochloric add (Analar Grade - SG 1.18) by diluting 86 ml 
and 430 ml each in 1 litre of deionized water. These solutions were stored 
in a glass stoppered glass bottles.
Scintillation fluid, toluene based contained PPO (2.5-diphenyl-oxazol)
(5g.per litre) and POPOP {l,4-di[ 2-(5-phenyl-oxazalyl)-benzene) (0.05 g. per
litre). This solution was used to suspend all radioactive labelled amino
adds while their radioactivity was being assessed in a liquid scintillation
spectrophotometer. The counts per minute (cpm's) were converted to
dpm's (disintegrations per minute) by taking account of the efficiency of
14the machine for counting C-labelled substrates. Sodium hydroxide (1.0
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M) was prepared by dissolving sodium hydroxide (40g.) in one litre of 
deionized water.
Standard solutions of single amino acids (50 nm ol/100 ul) were prepared 
by dissolving separate crystalline amino acids (2.5 umol) in hydrochloric 
acid (5 m l) (0.1 M). These solutions were stored at -20 °C.
Thin Layer Chromatographic Plates. These were purchased from 
Inderman and Co. Ltd., Central Avenue, East Molesly, Surrey, England, 
and were thin layers (2 .0mm) 20 cm x 20  cm of silica.
Purification of 14C-labelled amino acids. Valine, Leucine, Isoleucine and 
Cycloleucine. Prior to use of these amino acids they were purified by TLC.. 
Of each (stock standard) lOul was spotted using disposable microsampling 
pipettes on a thin layer using a TLC tray. Rapid drying was effected by 
plying a stream of hot air over the plates. Non-radioactive standards were 
spotted on the side lanes. The plates were developed in various solvent 
systems (Table 2.1) until a single peak of Gaussian form was obtained on 
radiochromatographic scanning. The side-lanes of each plate were sprayed 
with ninhydrin to locate individual amino acids (unlabelled). Using these 
loci in conjunction with the chromatographic peaks a precise locus for 
each radioactive amino acid was identified.
The silica over each radioactive amino acid as indicated by the base of each 
peak, was removed by scraping and suction into an elution thimble and 
the amino acid eluted with aqueous ethanol (70 percent) ( 5 x 2ml). The 
effluent collected in tubes was blown to dryness under a stream of 
nitrogen, the tubes being placed in a hot water bath at 40 °C. The dried 
individual amino acids were dissolved in aqueous ethanol (2  percent 
ethanol in water) (2ml) and stored at -20 °C as working standards.
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Table 2.1 Rf values of the amino acids included in the study in different 
solvents
Amino acid Solvent A Solvent B Solvent C
Alanine 0.149 0.255 0.430
Glycine 0.101 0.235 0.398
Valine 0.268 0.361 0.547
Threonine 0.165 0.243 0.479
Serine 0.125 0.230 0.456
Leucine 0.392 0.480 0.610
Isoleucine 0.335 0.471 0.579
Cyclo-leucine 0.394 0.459 0.612
Lysine 0.100 0.070 0.031
Tyrosine 0.321 0.485 0.598
A—n-butanol/acetic acid/water (60/15/25) 
B—n-butanol/acetic acid/water (80/20/20) 
C—ethanol/water (70/30)
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An aliquot (100 ul) of the working standard was taken for counting by 
liquid scintillation spectrophotometry and by calculation the new specific
r 14activities of the individual solutions were determined. The example for 
C - Cycloleudne is given below.
10 ul stock standard (spotted on T.L.C) contain 1.23 x 106 dpm*s
100 ul working standard (after purification) contained 59500 dpm's
Thus the working standard (2ml) contains 20 x 59500 dpmfs= 1.19 x 106.
Thus the recovery rate after purification = 1.19 x 10 6 /1.23x 10 6 = 96.75 
percent.
Preparation of Dowex 50 W X8 (H+) Resin
The resin as purchased was suspended in water (deionized) and allowed to 
settle after gentle shaking. The supernatant fluid containing amino acids, 
peptides and proteins was removed by suction. This procedure was 
repeated three times using Dowex (20 g) in deionized water (100 ml). 
Then followed washing of the resin with sodium hydroxide solution (1M: 
3ml) and its removal by suction followed again by water washing (50 ml) 
and its removal by suction. Thereafter the resin was washed with 
hydrochloric acid (5M : 30 ml) then with deionized water until the 
washings were neutral to litmus paper. The prepared Dowex was kept 
under water until required for use.
Preparation of Ion-Exchange Column
Pasteur pipettes (133, 134, 135) have been recommended as suitable for 
columns and I found this practical as an adopted practice in the
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Laboratories of the Department of Child Health. Short columns are at any 
rate recommended for the clean-up of samples when using ion exchange 
resins in the quantitation of amino acids (136).
The narrow end of the pipette was partially occluded with a pledgelet of 
glass wool so as to allow a flow rate of 15-20 drops per minute. The 
column was supported in a wooden rack (Figure 2 .2 ). The aqueous 
suspended resin was placed in the pipette to a height of 1.5 cm and the 
walls of the pipette were washed down with water. When the Dowex 
settled a small disk of Whatman No 1 filter paper was placed on top of the 
support so that the surface would not be disturbed during the application 
of the test material. The resin was then washed with hydrochloric acid 
(1M; 2 ml) followed by washing with water (3 x 2ml) or until the washings 
were neutral to litmus paper. The column was now ready for sample 
addition.
A frozen plasma sample was allowed to thaw at room temperature. An 
aliquot(250 ul) was pipetted into a test tube containing 14C-cycloleucine (200 
ul of working standard or 119000 dpm's). Acetic acid (5M; 500 ul) was then 
added so as to adjust the plasma pH to between 2.0 to 2.5. The contents of 
the tube were transferred quantitatively on to the surface of the exchange 
resin in the Pasteure pipette. Since the free amino acids are strongly 
adsorbed by the sulphone group (SO3-) of the resin, the nonabsorbed 
materials were removed by simple deionized water washing ( 4 x 2  ml). 
Meantime the column eluate was being collected in 2 ml aliquots. Next 
ammonium hydroxide solution (2 M; 5 x 2 ml) was added to the column to 
elute the adsorbed amino acids and again 2 ml aliquots of the eluate were 
being collected. The 2 ml aliquots were collected in counting vials. Each 
aliquot was blown to dryness using a stream of nitrogen while the vials
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Figure 2.2 Ion-exchange Chromatography
94
were held securely in a water bath at 40 °C. The contents of the vials were 
then exsiccated for four hours in a dessicator. Scintillant fluid (10 ml) was 
then added for counting in the liquid scintillation spectrophotometer. The 
radioactivity (expressed as dpm's) in each aliquot of the column is shown 
in Table 2.2. It will be seen that the radioactivity is eluted in the 
ammonium hydroxide aliquots No's 1,2 and 3 only and the total recovery 
is around 99 percent of that added to the column originally. This 
experiment was repeated but using 20ul (11900 dpms) and varying 
volumes of patient's plasma so as to test the loading of the column and its 
capacity to adsorb varying masses of amino acids. The results from this 
exercise are shown in Table 2.3.
Derivatisation of Amino Acids and percentage derivatisation
Because of the high melting point of free amino acids they cannot be 
applied directly to the column in a GLC system. They must be derivatised. 
Impurities in a mixture of free amino acids do interfere with the efficiency 
of derivatisation, hence the purification procedure of the Dowex 50 
column.
Heptafluorobutyrates have been found to be suitable esters of amino acids 
for GLC separation and quantitation (132, 137, 138). The total formation of 
suitable derivatives involves the esterification of the amino acids with 
isobutyl alcohol followed by acylation with heptafluorobutyric anhydride. 
So is formed the heptafluorobutyryl isobutyl amino acid esters. These 
amino acids taken from the Dowex 50 column (duplicate samples ) were 
taken to absolute dryness using nitrogen and dessication and to the 
sealable ampoules was added acidified isobutanol (250 ul ). Acidified 
isobutanol was prepared by the addition at 0s °C of acetyl chloride (275 ul)
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Table 2.2  Percentage recovery of the ammonium hydroxide elute from 
ion-exchange column of 14C-Cycloleucine (119000 dpms).
Aliqouts Dpms Percent recovery
1 94010 79
2 20230 17
3 3451 2.9
Total 117691 98.9
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Table 2.3 Percentage recovery of 14C-Cycloleucine(11900 dpms) from the
ion-exchange column contained in different amounts of pooled plasma
f
(duplicate).
Plasma 100 200 400 500
volume (ul) A B A B A B A B
dpms in elute 11724 11650 11519 11868 11763 11622 11762 11531
Recovery % 98.52 97.90 96.80 99.73 98.85 97.66 98.84 96.90
Mean of duplicate 98.21 98.27 98.26 97.78
Mean ±SD 98.15±1.02
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dropwise to isobutanol (1 m l ). The ampoules were flushed with nitrogen, 
immediately sealed and after mixing, the ampoules were incubated at 130 
°C for 30 minutes. The samples were allowed to cool and the mixtures 
were freeze dried. To the dried residues heptafluorobutyric anhydride (100 
u l ) was added, the contents mixed, flushed with nitrogen, the ampoules 
sealed and incubated again at 150°C for 10 minutes. By this the 
heptafluorobutyryl-isobutyl esters were formed. After cooling the contents 
of the ampoules were completely dried and to the residues ethyl acetate in 
appropriate amount was added to each. To test the percentage 
derivatisation 11900 dpms were added to varying volumes of column 
purified pooled plasma and the samples derivatised in the usual manner 
described above. After derivatisation the dried samples were taken up (in 
dichloromethane) for spotting on TLC plates. These were then developed
in solvent system:- chloroform/isobutanol/acetic acid ( 95/5/1) followed by
14scanning, and the silica over the C-cycloleucine was removed, eluted and 
the residue subjected to scintillation counting. The recovery values are 
shown in Table 2.4 giving an average of 97.76 per cent.
Column Separation of the Derivatised Plasma Samples
14Although I have used C-cycloleucine for recovery experiments related to 
the Dowex column and the derivatisation procedure, my final 
quantitation method was by internal standard and relative molar 
response. Internal standardization is the best method for obtaining 
accuracy, precision and reliability in GLC analyses. By this the internal 
standard is added to the sample at the beginning of the procedure and 
taken through the entire steps. Certain criteria for the internal standard 
must obtain. For example its chemical structure and properties should 
be close to those of the test material. Its retention time should be separate
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Table 2.4 The assay of the efficiency of derivatisation procedure
14(11900) dpms originally added to the column as C-cycloleucine)
Plasma volume in 100 300 4 0 0 500
duplica (ul) A B A B A B A B
dpm s after derivatisation 11722 11616 11796 11443 11360 1 1767 11732 11514
% derivatisation 98 .50 97.61 99.13 96.16 95 .46 98 .88 99 .59 96.76
Mean of duplicate 98.06 97.65 9 7 .1 7 9 7 .68
Total mean % ± SD 9 7 .76±1 .51
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from those of the sample but the difference should not be great. Finally it 
must be stable under the GLC conditions used. Cycloleucine answered 
these requirements. The internal standard method of assay eliminates the 
need for corrections due to evaporation, spillage, recovery rates etc., and is 
not affected by minor changes in the GLC conditions (139).
In this work unlabelled cycloleucine (20-50 nmol) was added to each 
unknown plasma sample as the internal standard and taken through the 
whole procedure. Additionally this internal standard (50 nmol) was added 
to the mixture of standard amino acids (of each 2.5 umol per ml) before 
the derivatisation. Following derivatisation the samples were brought to 
dryness and reconstituted with ethyl acetate (250 ul). Thus the mixture had 
a concentration of lnmol per lul. Aliquots of the derivatised standards 
(2.5 ul) and of the unknown samples similarly reconstituted (2.5 - 5ul) 
were injected onto the GLC. column under the following running 
conditions.
Nitrogen flow rate 25 ml per minute.
Hydrogen flow rate 30 ml per minute.
Air flow rate 300 ml per minute.
Injector temperature 250 °C.
Detector temperature 300 °C.
Column Oven temperature 100 °C for 3 minutes
programmed between 100°C and 250°C increasing at 2°C per minute.
Typical tracings of both standards and unknown samples are shown in 
Figures 2  (3 and 4). The reason for using temperature programming is that 
each compound tends to be eluted at its optimum temperature. 
Throughout the period of this work the stability of the GLC apparatus and
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the satisfactoriness of the running conditions were occasionally checked by 
processing varying amounts (nmols) of the amino acid standard esters. 
The linearity of the detector is confirmed by the data of Figure 2.5. I have 
used the method of the peak height for it has been found acceptable (138).
The order in which each amino acid was registered by the detector and the 
corresponding peak was studied by processing individual amino acid 
esters. Thus the composite profile of the total amino acid peaks was built 
up for the routine work. The quantitation of the amino acids in the 
plasma samples was calculated by comparison of the relative molar 
response (RMR) of the individual amino acids to the internal standard 
cycloleucine (138). The RMR values of the amino acids studied in relation 
to the internal standard (cycloleucine) are shown in Table 2.5.
Amino acid molar response = peak height per mole of amino acid.
Relative molar response =Amino acid molar response per internal 
standard molar response. Using the relative molar response of the 
individual amino acids in relation to cycloleucine as the internal standard 
it was possible to calculate the plasma amino acid concentration in each 
sample depending on the plasma volume originally available and the 
amount of the internal standard added to the unknown plasma sample
RMR of a.a (X)= Response of Imol of a.a(X)
Response of lmol of cycloleucine(i.s)
= Peak Ht.of(X)/moles of (X) injected 
Peak Ht. of (i.s)/moles of (i.s) injected
Nanomoles in the unknown sample=
RMR of (X) in the sample x nmoles of (i.s) added to the sample 
RMR of (X) in the standard solution
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So the concentration of the amino acid in the plasma=
nmoles in the plasma sample X 1000 = nmol/ml (umol/1)
volume of plasma taken (ul)
Statement of the Method
1. Cycloleucine (20-50 nmol) and acetic acid (5 M; 500ul) were added to 
plasma (100-250 ul) in a test tube and the contents mixed.
2. The mixed contents were applied quantitatively to the Dowex 50 W 
X8 (H+) column.
3. Deionized water (4 x 2ml) was passed through the column and these 
washings were discarded.
4. Ammonium hydroxide (2M; 4 x 2ml) was used to elute the amino acids 
from the support and the total collected in a glass ampoule.
This eluate was blown to dryness and the residue excicated in a dessicator.
6 . Hydrochloric-isobutanol (250 ul) was added to the dried residue in the 
ampoule, air expelled with a stream of nitrogen and the ampoule sealed 
immediately. The contents were mixed
7.—and placed in an oven at 130 °C for 30 minutes.
8 . Cooling was then allowed till room temperature was reached.
9. The excess reagents were then removed by freeze drying.
10. Heptafluorobutyric anhydride (100 ul) was then added to the completely 
dried sample, the ampoule again flushed with nitrogen, sealed, the 
contents mixed and the ampoule incubated at 150°C for 10 minutes.
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11 .The ampoule was then allowed to cool to room temperature before 
opening.
12.Excess reagents were again removed by freeze drying - a process 
requiring care because of frothing.
13. Ethyl acetate (100-250ul) was then added to the dried residue and 2-5 ul 
taken for G.L.C. analysis.
14.The peak heights of the individual amino acids were measured and the 
calculations were made as above.
15.Accompanying each batch of samples a new set of standards was 
processed similarly because after esterification certain amino acids may 
lose their detectability e.g. lysine and cystein lose 15 percent of their
detectability within 12 days while that of methionine and arginine is lost
\
within a few days.
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Figure 2.5 Detector linearity for the heptafluoro- 
butyrylisobutyl amino acid derivatives.
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Table 2.5 The relative molar responses of the heptaflourobutyryl-isobutyl 
esters of the amino acids in relation to cycloleucine as the internal 
standard.
Amino acid RMR m ean value (n=35) Standard Deviation
Alanine 0.811 0 .0 5 7
Glycine 0 .610 0 .1 8 4
Valine 0.901 0 .0 3 2
Threonine 0 .877 0 .04
Serine 0.839 0 .0 3 8
Leucine 1.011 0 .116
Isoleucine 0.988 0 .1 3 2
Lysine 0 .957 0 .0 8 7
Tyrosine 1 .076 0 .1 8 8
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Principles of Somatostatin Assay
The availability of synthetic somatostatin made it possible to generate 
antiserum against it and this led to the development of various 
radioim munoassay techniques. Reliable and easy methods for 
somatostatin assay in tissue extracts, culture media and tissue perfusates 
are available (140) but its assay in plasma presents some difficulties. It has 
been proved by several investigators that proteases in unextracted plasma 
could degrade both native somatostatin and labelled analogues used as 
tracers in the assay (141,142,143). Additionally large somatostatin 
molecules may interfere with the specificity of the method.
Moreover plasma contains somatostatin binding protein (144) and other as
yet poorly characterized substances which interfere with antibody binding
(145,146). Extraction of plasma before performing the radioimmunoassay
has gone a long way to solving these problems (145,146). The method of
assay used in this work utilized extracted plasma, acetone and petroleum
ether being the extractant (147). Thus after extraction, the cleaned-up
plasma is subjected to a radioimmunoassay to which is added
125simultaneously rabbit anti-somatostatin antibody and I somatostatin
followed by overnight incubation at 4^C. The somatostatin in the plasma
sample is allowed to react with the rabbit antisomatostatin serum. The
remaining free moieties of the rabbit antisomatostatin then reacts with the 
125 I-somatostatin. Phase separation is effected by the addition of a 
complex of goat anti-rabbit serum, carrier rabbit serum and a polyethylene 
glycol(GAR-PPT). After 15-25 minutes of incubation, centrifugation is 
carried out resulting in the formation of a precipitate which contains the 
radioactive somatostatin which has reacted with the rabbit anti­
somatostatin serum. Radioactivity in the precipitate may then be counted.
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The higher the radioactivity count in the precipitate the greater is the
125antibody which reacts with the I somatostatin, and thus the less is the 
somatostatin in the test plasma sample.
Procedures of the assay
A- Extraction procedure. Plasma (1 ml) was pipetted into a chilled glass 
tube. Cold acetone (2 ml) was added dropwise while continuously shaking 
the tube. After thorough mixing, the sample was centrifuged for 15 
minutes. The supernatant phase was decanted into another chilled glass 
tube. Petroleum ether (4 ml) was added and the contents mixed followed 
by centrifugation. The upper ether layer was aspirated and discarded. The 
aqueous layer was freeze dried and stored at -20° C.
B. Radioimmunoassay procedures
Somatostatin assay was by a KIT procedure and the reagent used were:-
1. 1% BSA- Borate Buffer. BSA-borate buffer with merthiolate added 
(lyophilized) was reconstituted with deionized water (50 ml) and allowed 
to stand for 15-20 minutes until completely dissolved. This was then 
stored at -20° C.
2. Rabbit antisomatostatin serum. This was diluted in BSA-borate buffer 
with merthiolate added (lyophilized). The contents of the vial were 
reconstituted with deionized water (10 ml) and allowed to stand for 15-20 
minutes until completely dissolved and then stored at -20° C.
125 1253. I-somatostatin. Synthetic (Tyr-1) somatostatin labelled with I and
diluted in BSA-borate EDTA buffer with merthiolate added (lyophilized) 
was reconstituted with de-ionized water (10 ml) and was allowed to stand 
for 15-20 minutes until completely dissolved and then stored at -20°C..
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4.Goat anti-rabbit precipitating complex. Normal rabbit serum pre­
precipitated with goat anti-rabbit serum and polyethylene glycol (PEG) 
was diluted in BSA-borate buffer with merthiolate added (lyophilized). 
Each vial was reconstituted with deionized water (35 ml) and the contents 
mixed thoroughly until the suspension appeared homogeneous. Each vial 
was then allowed to stand at room temperature for a minimum of 30 
minutes with occasional mixing. The vials were then stored at -20° C.
5. Somatostatin standard (500 pg per ml). Synthetic somatostatin diluted 
in BSA-borate buffer with merthiolate added to obtain a concentration of 
500 pg per ml (lyophilized) was provided. The vial was reconstituted with 
deionized water (2ml) and allowed to stand for 15-20 minutes until 
completely dissolved.
Steps of the assay procedure
1. In order to obtain a standard curve, serial dilutions of the somatostatin 
standard were prepared according to Table 2.6
2. The freeze dried plasma residues were then dissolved in BSA-borate 
buffer (1 ml). The tubes containing them were placed in an incubator at 
37° C. for 10 minutes, then placed in racks over crushed ice.
3. The above-mentioned reconstituted reagents were then allowed to thaw 
completely and then mixed gently. They were then placed over crushed ice 
until use.
4. Numbered tubes (12x75mm) were set up in duplicate according to the 
protocol in Table 2.7 and the rack of tubes was placed on crushed ice.
5. Reagents were added as shown in Table 2.7 and then incubated at 4° C 
for 24 hours.
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6 . After incubation goat anti-rabbit precipitating complex(500ul) was added 
to all the tubes except the total count tubes. The contents were well mixed.
7. Thereafter followed an incubation period of 25 minutes at 25° C.
8 . Centrifugation at 760 x g for 20 minutes then followed at 20°C. The 
supernatant layer was immediately and completely decanted from all the 
tubes except for the total counts tubes. This was effected by inverting the 
tubes for a maximum of 2 minutes. The rims of the tubes were blotted to 
remove any drops of supernatant that may have remained.
10. In a Gamma Scintillation counter the precipitate of each tube and the 
total counts tubes were assayed for radioactivity (dpm’s).
Procedure for calculating values of unknowns
Firstly a calibration curve was constructed by plotting the degree of binding 
against the stated concentrations of the calibration standards Figure 2.6 . 
To obtain the percentage binding the average cpm's of each standard was 
calculated. This was divided by the average cpm's of the total count tubes.
Percentage binding = cpm's of standards or unknown x 100
cpm's of total count tubes
The concentration of somatostatin in the unknown plasma samples was
then determined from the plotted curve.
Recovery rate of somatostatin from the extracted plasma
This was done by adding varying amounts of synthetic somatostatin (25- 
lOOpg/ml) to plasma samples containing known values of somatostatin 
the samples were then extracted and processed as described before.The 
mean of the recovery rates was 95.9 % as shown in Table 2.8
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Table 2.6 Preparation of somatostatin standard tubes.
Procedures concentration obtained
1. Add 500 ul of 500 pg/m l of standard to 
500 ul of BSA-borate buffer and mix well.
250 pg/m l
2 . Add 500 ul of 250 pg/m l of standard to 
500 ul of BSA-borate buffer and mix well.
125 pg/m l
3. Add 500 ul of 125 pg/m l of standard to 
500 ul of BSA-borate buffer and mix well.
62.5 pg/m l
4. Add 500 ul of 62.5 pg/m l of standard to 
500 ul of BSA-borate buffer and mix well.
31.2 pg/m l
5. Add 500 ul of 31.2 pg/m l of standard to 
500 ul of BSA-borate buffer and mix well.
15.6 pg/m l
6 . Add 500 ul of 15.6 pg/m l of standard to 
500 ul of BSA-borate buffer and mix well.
7.8 pg/m l
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Table 2.8 Recovery rate of the synthetic somatostatin extracted from the 
plasma.
Background
(Pg)
standard 
added (pg)
expected 
value (pg)
measured
value(pg)
percent
recovery
5 25 30 29 96.7
5 50 65 62 95.4
5 100 105 107 101.9
8 25 33 30 90.9
8 50 58 54 93.1
8 100 108 101 93.5
12 25 37 35 94.6
12 50 62 59 95.2
12 100 112 114 101.8
mean recovery rate% 95.9 ± 3 -75
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CHAPTER THREE
Results
In this Chapter I shall present firstly the effects of withdrawing cadaveric 
growth hormone from the patients studied and their response to restarting 
recombinant growth hormone after a lapse of nine months. Following 
this presentation there will be a statement of the corresponding trends in 
plasma somatostatin concentrations and this will be followed by a study of 
the effects of both growth hormone administration and plasma 
somatostatin on the plasma amino acid concentrations with particular 
reference to some of the indispensable amino acids.
In Table 3.1 and 3.2 (derived from the anthropometric data in Appendix 
Tables A1 & 2) are data which highlight the changes in the height standard 
deviation scores (SDS) consequent on the withdrawal and restarting of 
growth hormone in the boys and girls who were judged to have idiopathic 
growth hormone deficiency. These patients had all been accepted by the 
National Health Service Growth Hormone Committee as suitable for 
growth hormone therapy and variously had between two weeks and eight 
years of treatment prior to withdrawal of cadaveric growth hormone. 
Nonetheless at that point of withdrawal the SDS's are recorded without 
reference to their former period of treatment.
To remind the reader of the meaning and significance of the SDS, a brief 
explanation is offered. The SDS for height is the relationship of the 
recorded patient height to the mean for the patient's age according to the 
formula:
SDS = observed height - mean height for patient's age
one standard deviation
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Table 3.1 Height standard deviation scores for male children with
idiopathic growth hormone deficiency (IGHD) during the period of
review. (See Appendix Table A. 1).
Height Standard Deviation Scores
PATIENT Ch. age (Year) April 1985 Jan 1986 Jan 1987
1-AB 2.16 -4.51 -4.87 -3.74
2-JC 9.39 -2.47 -2.99 -2.51
3-AG 10.88 -3.68 -3.69 -3.07
4-ALB 11.49 -3.54 -3.61 -3.40
5-NMcQ 12.57 -3.63 -3.95 -3.96
6-CMcG 12.92 -2.43 -2.64 -2.24
7-RH 12.94 -3.28 -3.60 -3.49
8-CG 13.65 -2.56 -2.77 -2.56
9-NC 13.92 -1.46 -1.75 -1.50
10-SS 14.15 -3.87 -4.48 -4.81
11-BL 15.02 -4.51 -5.10 -5.41
12-IMcC 15.32 -2.93 -3.55 -3.37
13-DB 16.73 -2.95 -2.96 -2.82
14-MMcG 17.01 -4.47 -4.11 -4.02
Mean -3.30 -3.57 -3.35
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Table 3.2 Height standard deviation scores for female children with
idiopathic growth hormone deficiency (IGHD) during the period of review.
Height Standard Deviation Scores
PATIENT Ch.a/Year April 1985 Jan 1986 Jan 1987
1-SS 5.77 -3.80 -4.25 -2.66
2-CS 6.51 -1.32 -1.61 -1.29
3-LB 6.55 -3.16 -3.79 -2.76
4-TG 9.95 -1.62 -2.14 -1.83
5-AQ 15.40 -4.95 -4.15 -3.20
Mean -2.97 -3.19 -2.35
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A negative value means that the patient's height is less than the mean or 
50th centile. The more negative the score, the further is the patient's 
height below the mean. A SDS which becomes less negative means that 
the patient's height is coming nearer to the 50th centile. A patient's height 
could be increasing at the average annual rate, while the actual height is 
below the 50th centile but increasing parallel to it. Such a patient's SDS for 
height will not change. It follows that a; SDS which improves minimally 
indicates that only small gains are being achieved over the annual growth 
velocity. For easy understanding the reader may think of one standard 
deviation as being approximately 6 cm but one standard deviation 
throughout the period of child growth ranges from 3.30 cm at an age of 2 
years to 8.31 cm at 14 years of age(131).
A study of Tables 3.1 and 3.2 shows that at the time of withdrawal of 
cadaveric growth hormone the height SDS's were all negative ranging 
from -4.51 to -1.46 (boys) and for girls -4.95 to -1.32. Also in Tables 3.1 and 
3.2 the means for these SDS's are shown and it is of considerable interest 
that for the boys an initial (1985) SDS of -3.3 worsened on withdrawal of 
cadaveric growth hormone to -3.57 at January 1986 with some recovery 
following a year of treatment with recombinant growth hormone to -3.35 
(Jan 1987). Thus the restarting of growth hormone did no more than 
correct the failure to gain height during the withdrawal period. A similar 
conclusion can be made from the data for girls (Table 3.2 ) where the mean 
height SDS's dipped from -2.97 in April 1985 to -3.19 at Jan 1986 and 
recovered to -2.35 at Jan 1987. An immediate conclusion is that growth 
hormone therapy once started should not be interrupted. Subsequent 
years of treatment will therefore be required to bring the actual heights to 
as near normal as possible.
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In Tables 3.3 and 3.4 are the height SDS from the same boys and girls 
respectively shown alongside the achievement in the annual growth 
velocities (cm/year) for the same three phases of review. Apart from 
patients AG, MMcG and BL (boys) and SS and AQ (girls), all patients 
showed a "fall off" in their annual growth velocities. Patients SS and AQ 
only received cadaveric growth hormone for 2 weeks before withdrawal of 
therapy and the fact that their AGV's increased during the withdrawal 
period may reflect the phenomenon of the increased growth velocity 
formerly observed in the 'run in' pretreatment year, thought to be due to 
increased parental attention to the child. Patient RH who only had 
replacement therapy for two weeks showed a falling AGV during 1986 
which is surely the progressive effects of growth hormone deficiency.
Now  if it had been expected that following the recommencement of 
treatment with recombinant growth hormone, a catch-up growth would 
have followed, then this only occurred in three patients AB and CMcG 
(boys) and SS (girl). It should be understood that catch-up growth here 
means a growth velocity sufficient to compensate for the loss of growth 
during the withdrawal period plus a normal annual increment for the year 
of renewed treatment. If we now consider the mean annual growth 
velocities for both boys and girls, it will be seen that for boys a mean 
annual growth velocity of 5.5 cm/year (range 1.8 - 10.0) fell to 2.8 cm/year 
(range 0.8 to 4.2 cm/year) and was restored to 6.07 cm /y (range 0.9 to 10.0 
cm/yr) (Table 3.3 ). Similarly significant means for girls (Table 3.4) are 5.76 
cm/yr (range 1.5 to 10.10 cm/yr) falling to 3.6 cm/yr (range 1.1 -  7.1 cm/yr), 
recovering to 8.14 cm/yr (range 5.7 -  13.4 cm/yr).
If we now look at the individual patient response to the withdrawal restart 
episode, it will be seen that some patients did better than others.
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Table 3.3 Height standard deviation scores for males with idiopathic
growth hormone deficiency related to their annual growth velocities
(AGV) during the period of review.
Height SDS. AGV. Cm/Y.
Patients Apr/85 Jan/86 Jan/87 Apr/85 Jan/86 Jan/87
1-AB -4.51 -4.87 -3.74 8.5 4.0 10.0
2-JC -2.47 -2.99 -2.51 5.1 4.13 5.00
3-AG -3.68 -3.69 -3.07 2.4 3.2 8.50
4-ALB -3.54 -3.61 -3.40 10.0 2.7 6.20
5-NMcG -3.63 -3.95 -3.96 5.6 0.8 6.00
6-CMcG -2.43 -2.64 -2.24 5.0 3.3 10.50
7-RH -3.25 -3.60 -3.49 3.6 2.0 8.00
8-CG -2.56 -2.77 -2.56 8.7 4.2 5.70
9-NC -1.46 -1.75 -1.50 5.6 4.0 7.90
10-SS -3.87 -4.48 -4.81 6.1 1.7 7.20
11-BL -4.51 -5.10 -5.41 1.8 2.8 4.20
12-IMcC -2.93 -3.55 -3.37 3.3 1.9 3.70
13-DB -2.95 -2.96 -2.82 8.7 0.9 1.20
14-M M cG -4.47 -4.11 -4.02 2.6 3.5 0.90
Mean -3.30 -3.57 -3.35 5.5 2.8 6.07
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Table 3.4 Height standard deviation scores for girls with idiopathic growth
hormone deficiency related to their annual growth velocities (AGV)
during the period of review.
Height SDS. AGV. Cm/Y.
Patients Apr/85 Jan/8 6 Jan/87 Apr/85 Jan/8 6 Jan/87
1-SS -3.80 -4.25 -2.66 1.50 3.87 13.4
2-CS -1.32 -1.61 -1.29 7.70 4.00 6.60
3-LB -3.16 -3.79 -2.76 10.10 2.10 7.80
4-TG -1.62 -2.14 -1.83 7.60 1.10 7.20
5-AQ -4.95 -4.15 -3.20 1.90 7.10 5.70
Mean -2.77 -3.19 -2.35 5.76 3.60 8.14
12 2
It is now convenient to separate these two classes.
In Tables 3.5 and 3.6 are data for those children whose annual growth 
velocities were sufficiently good on restarting recombinant growth 
hormone to improve their 1987 height SDS's beyond those of April 1985. 
The respective mean AGVs for boys (Table 3.5) are 6.19, 2.98 and 6.40 cm 
per year, with the mean height SDS's improving from -3.42 to -3.17 (an 
improvement of +0.25). For the girls in Table 3.6 the corresponding values 
are 5.3,4.27 and 8.4 cm/year, with height standard deviation scores moving 
from a mean of -3.31 to -2.48 (gains +0.83). In Table 3.7 are the 
corresponding data for those children who fared less well. Note that their 
mean annual growth velocities, having fallen from 5.00 cm/year to 2.35 
cm/year during the withdrawal period, seemed to increase slightly during 
the period of recombinant growth hormone treatment to 5.89 cm/year i.e 
above the April 1985 level, but this was not sufficient to improve their 
height SDS's of -3.34 (Jan 1987) compared with -2.93 in April 1985 (loss of - 
0.41). The important feature between these good and poor responding 
groups is that the loss of linear growth was greater during the withdrawal 
period in those whose progress fared less well (cf Table 3.5 (2.98 cm /year) 
and Table 3.6, (4.27 cm/year) with 2.35 cm/year in Table 3.7.
I will now present data for the plasma somatostatin concentrations in 
these two groups of patients. Firstly however the reader is reminded that 
in the healthy paediatric subjects the plasma concentrations of 
somatostatin are inversely correlated with chronological age. The 
regression line for plasma somatostatin concentrations in 89 normal 
subjects is shown in Figure 3.1. The age range is from 2.16 to 20 years.
The reader is reminded that the plasma somatostatin SDS is
The Patient's plasma SRIF value - the mean for age /  1 SD.
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Table 3.5 Height standard deviation scores related to the annual growth 
velocities (AGV) for boys with idiopathic growth hormone deficiency who 
had improved their height standard deviation scores during the period of 
review.
AGV Cm/Year Height SDS
Patients Pre 4/85 1 /8 6 1/87 4/85 1 /8 6 1/87
1-AB 8.50 4.00 10.00 -4.51 -4.87 -3.74
3-AG 2.40 3.20 8.50 -3.68 -3.69 -3.07
4-ALB 10.00 2.70 6.20 -3.54 -3.61 -3.40
6-CMcG 5.00 3.30 10.50 -2.43 -2.64 -2.24
7-RH 3.60 2.00 8.00 -3.25 -3.60 -3.49
8-CG 8.70 4.20 5.70 -2.56 -2.77 -2.56
13-DB 8.70 0.90 1.20 -2.95 -2.96 -2.82
14-MMcG 2.60 3.50 0.90 -4.47 -4.11 -4.02
Mean 6.19 2.98 6.40 -3.42 -3.53 -3.17
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Table 3.6 The Annual growth velocities of the girls with idiopathic growth 
hormone deficiency (IGHD) who at the end of the review period had 
improved their height SDS.
AGV cm/Year Height SDS
Patients Pre/85 1/1986 1/1987 4/1985 1/1986 1/1987
1 .SS 1.50 3.87 13.40 -3.80 -4.25 -2.66
2 CS 7.70 4.00 6.60 -1.32 -1.61 -1.29
3 . LB 10.10 2.10 7.80 -3.16 -3.79 -2.76
5 . AQ 1.90 7.10 5.70 -4.95 -4.15 -3.20
MEAN 5.30 4.27 8.40 -3.31 -3.45 -2.48
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Table 3.7 Height standard deviation scores related to annual growth
velocities (AGV) in those children with idiopathic growth hormone
deficiency who fared less well during the period of review.
Height SDS. AGV. Cm/Y.
Patients Apr/85 Jan/86 Jan/87 Apr/85 Jan/86 Jan/87
2-JC -2.47 -2.99 -2.51 5.10 4.13 5.00
5-NMcQ -3.63 -3.95 -3.96 5.60 0.80 6.00
9-NC -1.46 -1.75 -1.49 5.60 4.00 7.90
10-SS -3.87 -4.48 -4.80 6.10 1.70 7.20
11-BL -4.51 -5.10 -5.41 1.80 2.80 4.20
12-IMcC -2.93 -3.55 -3.37 3.30 1.90 3.70
4-TG(F) -1.62 -2.14 -1.83 7.60 1.10 7.20
Mean -2.93 -3.42 -3.34 5.00 2.35 5.89
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It will be remembered when thinking about standard deviation scores that 
±2.5 SDS ranges from above the 97th centile to below the 3rd centile. 
Abnormal plasma somatostatin concentrations will therefore be associated 
with SDS's = +2.5 and more. The actual plasma somatostatin 
concentrations together with their SDS's in my cohort of children are 
shown in Table 3.8 for the good responders and Table 3.9 for the poor 
responders.
In this light consider the data in Table 3.10 (good responders) where the 
now familiar annual growth velocities for the three periods of the survey 
are shown with the plasma somatostatin SDS's for the same three periods. 
It will be noticed that at no time were the plasma somatostatin 
concentrations outside the normal range (except LB"F" during 1986). 
Perhaps during the withdrawal periods there were slight but insignificant 
increases in the plasma concentrations as reflected by the SDS's.
A vastly different picture is shown by those patients whose linear growth 
did less well during the withdrawal period. These data are in Table 3.11. 
Notice firstly that the mean annual growth velocity fell markedly from 
5.00 cm/year to 2.34 cm/year during the withdrawal period. For the same 
period the mean plasma somatostatin SDS's increased slightly from +2.32 
to +2.76 before falling again to +2.24 after recommencement with 
recombinant growth hormone. The SDS of +2.76 is a significantly 
abnormal level. The means in Table 3.11 are for boys with data for one 
single girl added.
At this stage it is worthwhile posing some questions:
1). Do the differences in plasma somatostatin separate two groups of 
patients?
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Figure 3.1 Regression line between plasma somatostatin and 
chronological age for all the normal group.
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Table 3.8 Actual plasma somatostatin concentrations (pg/ml), and their
standard deviation scores for those children with idiopathic growth
hormone deficiency who fared well during the period of review.
April 1985 Jan 1986 Jan 1987
Patient SRIF
conc.
SDS SRIF
conc.
SDS SRIF
conc.
SDS
1-AB 21 -0.67 25 +0.80 19 - 1.01
3-AG 25 +2.38 18 +0.17 16 -0.30
4-A1B 20 +0.80 21 +1.31 23 +2.18
6 -CMcM 23 +2.11 21 +1.57 19 +1.11
7-RH 17 +0.10 18 +0.57 15 -0.23
8-CG 16 - 0.10 18 +0.70 17 +0.57
13-DB 15 +0.17 16 -0.67 09 -1.34
14-MMcG 16 +0.57 17 +1.04 12 +0.25
l-SS(F) 23 +0.57 27 +2.37 21 +0.38
2-CS(F) 20 -0.38 21 +0.23 24 +1.60
3-LB(F) 24 +1.14 28 +2.90 24 +1.64
5-AQ(F) 19 +1.56 15 +0.27 16 +0.92
Mean +0.69 +0.94 +0.48
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Table 3.9 Actual plasma somatostatin concentrations (pg/ml), and their
standard deviation scores for those children with idiopathic growth
hormone deficiency who fared less well during the period of review.
April 1985 Jan 1986 Jan 1987
Patient SRIF
conc.
SDS SRIF
conc.
SDS SRIF
conc.
SDS
2-JC 25 +2.08 24 +1.88 22 +1.41
5-NMcG 25 +2.71 27 +3.52 24 +2.71
9-NC 18 +0.60 21 +1.78 17 +0.64
10-SS 24 +2.68 26 +3.48 23 +2.68
11-BL 26 +3.52 27 +3.99 24 +3.18
12IMcC 22 +2.24 21 +2.04 23 +2.91
4-TG(F) 25 +2.44 25 +2.63 23 +2.14
Mean +2.32 +2.76 +2.24
1 3 0
Table 3.10 Plasma Somatostatin concentrations expressed as standard
deviation scores and annular growth velocities in patients with idiopathic
growth hormone deficiency who fared well during the period of review.
AGV Cm/Year SRIF SDS
Patients Apr/85 Jan/86 Jan/87 Apr/85 Jan/86 Jan/87
1-AB 8.50 4.00 10.00 -0.67 +0.80 -1.01
3-AG 2.40 3.20 8.50 +2.38 +0.17 -0.30
4-A1B 10.00 2.66 6.20 +0.80 +1.31 +2.18
6-MMcG 5.00 3.30 10.50 +2.11 +1.57 +1.11
7-RH 3.60 2.00 8.00 +0.10 +0.57 -0.23
8-CG 8.70 4.20 5.70 -0.10 +0.70 +0.57
13-DB 8.70 0.93 1.20 +0.17 -0.67 -1.34
14-NMcG 2.60 3.50 0.90 +0.57 +1.04 +0.25
1-SS 1.50 3.87 13.40 +0.57 +2.37 +0.38
2-CS 7.70 4.00 6.60 -0.38 +0.23 +1.60
3-LB 10.10 2.10 7.80 +1.14 +2.90 +1.64
5-AQ 1.90 7.10 5.70 +1.56 +0.27 +0.92
Mean +0.69 +0.94 +0.48
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Table 3.11 Plasma Somatostatin concentrations expressed as standard 
deviation scores and annular growth velocities in patients with idiopathic 
growth hormone deficiency who fared less w ell during the period of 
review.
AGV Cm/Year SRIF SDS
Patients Apr/85 Jan/86 Jan/87 Apr/85 Jan/86 Jan/87
2-JC 5.10 4.13 5.00 +2.08 +1.88 +1.41
5-NMcG 5.60 0.80 6.00 +2.71 +3.52 +2.71
9-NC 5.60 4.00 7.90 +0.60 +1.78 +0.64
10-SS 6.10 1.70 7.20 +2.68 +3.48 +2.68
11-BL 1.80 2.80 4.20 +3.52 +3.99 +3.18
12IMcC 3.30 1.90 3.70 +2.24 +2.04 +2.91
4-TG(F) 7.60 1.10 7.20 +2.44 +2.63 +2.14
Mean 5.00 2.34 6.00 +2.32 +2.76 +2.24
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In other words are there two groups of children with growth hormone 
deficiency i.e good and poor responders to therapeutic growth hormone 
administration? or could it be that the division is into those with 
neurosecretory growth hormone deficiency and those with pituitary 
failure of growth hormone synthesis?
2 ) Are there two groups of people, one with normally low  plasma 
somatostatin and another one with high plasma level (cf. hypo and hyper- 
cholesterolaemia)? If growth failure for either reason develops do those 
with high plasma somatostatin concentrations grow less well than those 
with low concentrations, or do they require a higher replacement dosage of 
growth hormone?
3) Could it be that high plasma somatostatin concentrations reflect high 
concentrations at the pituitary gland thus impeding growth hormone 
release? Other possibilities come from a fertile mind if perhaps 
imaginative and these will be considered later in discussion.
Somatostatin is recognised as a general inhibitory substance (Table 1.5). In 
this respect my interest is in the inhibition of absorption of amino acids 
from the intestines. Can it be shown that in those children who had high 
plasma concentrations of somatostatin there was an accompanying 
lowering of plasma amino acid concentrations?
Plasma amino acids in IGHD children
The actual plasma amino acid concentrations for the three periods of this 
study are shown in Appendix (Tables B.l-9) and the concentrations are 
expressed in micromoles per litre (umol/L). So as to be able to express 
these data as SDS's with a view to eliminate an age-dependent factor, I
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show in Table 3.12 and Table 3.13 the regression analyses data derived from 
the normal subjects for the indispensable and dispensable amino acids 
respectively and also in Figures 3.2 and 3.3 (p. 137-138) are examples of 
some regression lines showing the relationship between some of the 
amino acid concentrations and the chronological age. From these the 
SDS's for the indispensable and dispensable amino acids for the children 
with IGHD were calculated and are shown in Appendix Tables C 1&2. For 
convenience and ease of understanding the means of the SDS's for the 
'good' and 'poor' responders for the indispensable and dispensable amino 
acids are shown in Tables 3.14 & 3.15.
It will be seen in Table 3.14 (indispensable amino acids) that all the means 
are certainly within the 3rd and 97th centiles i.e. being within ±2.5 standard 
deviations. Nonetheless during the period of no treatment (Jan. 1986), the 
SDS's had worsened for all amino acids except threonine, indicating that at 
that time the actual concentrations of the individual amino acids had on 
average fallen. These changes are statistically significant except for 
threonine (Table 3.14). If this deficiency in these amino acids is 
maintained over long periods, then it is understandable that even with 
maximum utilization there will be a reduction in structures and functions 
which require a full complement of these indispensable amino acids. A 
further point of interest in this Table is that for those children who fared 
less well the means of the SDS's were more negative except for leucine and 
lysine at Jan. 1986 than for those children who fared well at that point in 
time. Additionally on restarting recombinant growth hormone the 
recovery of the plasma amino acid concentrations including leucine and 
lysine was greater in the 'good' responders than in the 'poor’ responders. 
Thus those poor responding children had at all times lower plasma amino 
acid concentrations of the indispensable amino acids than the good ones.
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Table 3.12 Regression analysis data of the relationship between plasma
indispensable amino acids and chronological age for the normal group.
Valine Leucine Isoleucine Threonin< i Lysine BCAA's
M 0.54 0.51 0.41 0.49 0.30 0.57
r F 0.51 0.55 0.44 0.57 0.30 0.60
M+F 0.55 0.52 0.45 0.52 0.33 0.60
M 0.29 0.26 0.17 0.24 0.09 0.32
r2F 0.24 0.30 0.19 0.32 0.09 0.36
M+F 0.30 0.27 0.20 0.27 0.11 0.36
M 168 83.0 41.2 65.9 96.4 292
a F 158 85.9 38.8 62.4 83.6 283
M+F 162 84.8 39.5 64.7 88.3 286
M 3.02 2.39 1.07 1.61 1.32 6.48
b F 3.27 2.36 0.98 2.25 1.55 6.61
M+F 3.27 2.33 1.10 1.83 1.63 6.69
M 24.81 21.54 12.31 15.22 22.57 49.43
SD.Y F 27.82 18.53 10.27 16.68 24.12 44.24
M+F 26.19 20.02 11.40 15.88 23.62 46.74
M = Male 
F = Female
BCAS = Sum of branched chain amino acids
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Table 3.13 Regression analysis data of the relationship between plasma
dispensable amino acids and chronological age for the normal group.
Alanine Glycine Serine Tyrosine
M 0.57 0.00 0.17 0.24
r F 0.63 0.24 0.30 0.42
M+F 0.61 0.14 0.22 0.35
M 0.32 0.00 0.03 0.06
2r F 0.40 0.06 0.09 0.18
M+F 0.37 0.00 0.05 0.12
M 244 260 111 48.10
a F 238 237 108 42.80
M+F 240 248 110 45.20
M 5.67 0.193 0.790 48.10
b F 5.54 2.093 1.46 42.60
M+F 5.75 1.100 1.01 45.20
M 44.02 34.96 24.69 0.403
SD.Y F 34.18 40.49 24.05 0.738
M+F 39.51 37.53 24.25 0.588
M = Male 
F = Female
BCAS = Sum of branched chain amino acids
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Table.3.14 Means of indispensable amino acid plasma concentrations in 
patients with idiopathic growth hormone deficiency (good and poor 
responders).
Valine Leucine Isoleucine Threonin* i Lysine
April/85 +0.09 -0.20 -0.11 -0.34 +0.08 Good
respondersJan/8 6 -1.15 -1.08 -0.96 +0.14 -0.83
Jan/87 -0.01 -0.18 +0.25 -0.14 +0.37
April/85 -0.45 -0.37 -0.18 -0.58 -0.38 Poor
respondersJan /8 6 -1.16 -0.85 -1.19 -0.20 -0.61
Jan /87 -0.19 -0.27 -0.34 -0.39 +0.06
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Table 3.15 Means of SDS's of the dispensable amino acid plasma 
concentrations in patients with idiopathic growth hormone deficiency 
(good and poor responders).
Alanine Glycine Serine Tyrosine
April/85 -0.05 -0.12 +0.12 +0.30 Good
respondersJan / 8 6 -0.79 -0.45 -0.40 +0.58
Jan /8 7 +0.13 -0.17 -0.01 +0.15
April/85 -0.63 -0.21 -0.30 -0.61 Poor
respondersJan /8 6 -0.87 -0.62 -0.45 -0.05
Jan /8 7 -0.57 -0.09 -0.01 -0.35
140
It is of extreme interest to correlate these plasma amino acid 
concentrations with the corresponding higher plasma somatostatin 
concentration (cf Table 3.9 and Table 3.14).
The question to which we will address ourselves in discussion is the true 
or theoretical relationship in terms of cause and effect of plasma 
somatostatin and plasma indispensable amino acid concentrations. If as 
we have observed that a rise in plasma somatostatin concentrations is 
accompanied with a lowering of the plasma indispensable amino acid 
concentrations, then this could be reflect on body status.
We will now consider the SDS's of the plasma concentrations of the 
dispensable amino acids in both groups. It will be seen from Table 3.15 
which brings together from Appendix Tables D 1&2. the means of the 
SDS's for these amino acid plasma concentrations, that firstly the 
concentrations of these amino acids was higher in the ’good' responders 
during the three periods of review than in the ’poor' responders, except for 
glycine and serine at Jan. 1987. Secondly on withdrawal of growth 
hormone the concentrations in both groups fell except for tyrosine whose 
plasma concentrations increased. On recommencing growth hormone all 
the dispensable amino acids rose from the lower 1986 value with exception 
of tyrosine which actually decreased. An attempt to explain this will be 
given later.
Nutritional Ratios
The reason for selecting the indispensable and the dispensable plasma 
amino acids above referred to was on their usage by other authors in the 
field of nutrition to calculate what has become known as nutritional ratios. 
Four of the nutritional ratios which have been accorded significance are:
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Ratio 1 which relates the total plasma branched chain amino acids to the 
sum of the plasma concentrations of alanine, glycine and serine.
Ratio 2 relates the total plasma branched chain amino acids to the sum of 
the plasma concentrations of glycine and serine.
Ratio 3 relates the plasma concentration of valine as an indispensable 
amino acid to glycine, a dispensable amino acid.
Ratio 4 relates the plasma concentration of tyrosine to that of glycine both 
of which are dispensable amino acids.
The crude data for this work for both groups (good and bad responders) are 
contained in the (Appendix Table B 1-9). Hence it will suffice to show the 
actual nutritional ratios for both groups of patients (good and poor 
responders) (Appendix Tables E 1-2). The means for these nutritional 
ratios for the three periods of observation are shown in Table 3.16. It will 
be seen that the ratios R1 and R2  fell significantly but the fall in R3 was not 
significant while R4 rose significantly in the good responding group 
during the period of treatment withdrawal. Following recommencement 
of growth hormone therapy the recovery of Rl, R2 and R3 were highly 
significant while R4 fell significantly back to the 1985 level.
Table 3.16. shows also the corresponding nutritional ratios for the 'poor 
responders'. Following the withdrawal of growth hormone only Rl fell 
significantly, while the falls in R2 and R3 were not significant. 
Interestingly R4 rose significantly. On resumption of therapy Rl, R2 and 
R3 showed a non-significant rise, while R4 showed a non-significant fall. 
These changes in the nutritional ratios for the two groups of patients will 
receive further consideration in discussion.
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Short stature in patients with cerebral tumours
Not all children with intracranial tumours present with short stature. 
Neurological signs and symptoms may be the salient features which bring 
the patients under scrutiny. Certain tumours like craniopharyngioma 
because of their site of occurrence frequently interrupt the hypothalamo- 
pituitary axis to give early reduction in growth hormone secretion which 
results in early evidence of growth failure. In such patients if there are no 
neurological signs, the child is commonly noted to be small for age and 
puberty may be delayed. Some degree of thyroid dysfunction may also be 
indicated. However if the neurological signs appear early with the tumour 
growth then it might be expected that linear growth need not be much 
affected. Such was the case with patients FI (LB) and F5 (AMcC) whose 
failing visual acuity was noted by the school teachers and early diagnosis 
made because of optic atrophy.
In this present series of patients with tumours the general rule was no 
matter the nature of the individual tumour, patients were near normal in 
height when the presentation was neurological whereas when short 
stature was marked, neurological signs and symptoms were absent or not 
part of the original complaint although elicitable on detailed neurological 
investigation.
The data regarding these patients will be presented in the same style as 
formerly since the reader will now be familiar with the deduction theory.
In Appendix Tables F.1&2 are the crude data for all the patients with 
cerebral tumours, male and female. It is immediately noted that at the 
time of cadaveric growth hormone withdrawal all but one child "FI" (LB)
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were in the pubertal age group chronologically. The maximum number of 
years of treatment was 8.16 years (range 1.00-8.16 years) post-operatively.
In Table 3.17 are grouped those patients whose height SDS for 
chronological age were improved at the period of last review when 
compared with their heights on withdrawal of cadaveric growth hormone. 
Table 3.18 shows the height SDS's for those patients who did less well. 
Those who improved their growth status on resumption of treatment 
with recombinant growth hormone did so by a mean for the group of +0.53 
SD’s while the others (Table 3.18) lost ground by a mean for the group of - 
0.82 SD’s.
It is of interest that those who improved their linear growth, all except 
Patient F4 (SD) (Appendix Table F.2) had craniopharyngioma. Thus it 
might be concluded that in terms of height for chronological age and post­
operative improvement with growth hormone therapy, the patients with 
craniopharyngioma improved on any height deficit present at the time of 
diagnosis. Scrutiny of these two Tables 3.17 & 18 shows that six patients 
out of seven who improved on their height status had a cranio­
pharyngioma while only one out of six who responded poorly to growth 
hormone treatment had a craniopharyngioma. Note the good increase in 
height (+2.08) of patient F5 (AMcC) (Table 3.17 and Appendix Table F.2).
Plasma Somatostatin concentrations (Tumours)
Crude data for these plasma somatostatin concentrations are in Appendix 
Tables G.l & 2  and Table 3.19 shows the SDS's for plasma somatostatin 
concentrations in relation to the annual growth velocities in those patients 
who improved their height status on treatment. All had normal plasma 
somatostatin concentrations except Patient F4 (SD) whose plasma value of
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Table 3.17 The annual growth velocities related to height standard
deviation scores for children with cerebral tumours who fared well to
growth hormone treatment during the period of review.
AGV cm/Year Height SDS
Patients April/85 Jan/8 6 Jan/87 April/85 Jan/8 6 Jan/87
l.DH 10.6 7.6 6.7 -0.69 -0.64 -0.68
6 .JMcD 5.8 2.1 2.6 -2.25 -2.10 -1.76
7.KT 4.2 1.6 6.5 -2.37 -2.21 -1.23
3.CI/F 4.5 1.7 4.3 -3.12 -3.46 -3.07
4.SD'F 4.0 3.2 3.2 -4.36 -4.30 -3.91
5.AMcC'F 8.1 1.7 6.8 +0.73 +0.95 +2.08
6,PC'F 4.0 1.3 0.00 -1.70 -1.53 -1.53
Mean 5.9 2.7 4.3 -1.97 -1.90 -1.44
*A11 the patients had craniopharyngioma except "F4" who had medullo- 
blastoma.
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Table 3.18 The annual growth velocities related to height standard
deviation scores for children with cerebral tumours who fared less well to
growth hormone treatment during the period of review.
AGV
cm/year Ht SDS
Patients April/85 Jan/8 6 Jan/87 April/85 Jan/8 6 Jan/87
2.DB 7 2.7 2,8 -2.25 -2.74 -3.44
3.MM 5 2.1 1.8 -1.76 -2.30 -3.01
4.PC 12 5.7 6 -3.00 -3.16 -3.27
5.TR 4.8 2.5 5.2 -2.09 -2.59 -2.50
l.LB'F 3 2.3 3 +0.25 -0.78 -0.68
2.AMcE'F 3.1 2.3 6.3 -3.70 -4.42 -4.57
Mean 5.8 2.9 4.2 -2.09 -2.67 -2.91
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somatostatin concentration was exceeding the normally accepted high 
concentration of +2.5 SD in 1985 and 1987. Interestingly she also had the 
worst height standard deviation scores, (Table 3.17) being -4.36 at April 1985 
and -4.30 at January 1986 and rising to -3.91 at January 1987 but still with 
markedly abnormal low height standard deviation score. Could it be that 
this girl was going to be of short stature because of her high plasma 
somatostatin concentration and that her tumour played little part in the 
pathology of her short stature? She was already very short statured on 
initial presentation despite her presenting features being neurological and 
hence coming early under scrutiny.
The plasma somatostatin concentrations were all within the normal range 
in those patients who responded poorly to growth hormone treatment 
(Table 3.20). It is difficult to draw many conclusions from a study of 
plasma somatostatin concentrations in this group of patients with 
tumours for their growth hormone deficiency was iatrogenic and not 
endogenous. Finally relative to this subject it is worth while sighting 
again the pathology data contained in Appendix Table F. 1&2 which will be 
dealt with later in the Chapter 4.
Plasma amino acid concentrations
Indispensable amino acids
While we have noted that in these patients with cerebral tumours there 
were no significant fluctuations in plasma somatostatin concentrations 
due to the temporary withdrawal of growth hormone therapy, a study of 
their actual plasma amino acid concentrations for both 'good' and ’poor’ 
responders are shown in Appendix Table H. 1-6. The calculated SDS's for 
these indispensable amino acids are shown in Appendix Tables 1.1 & 2.
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Table 3.19 The annual growth velocities related to plasma somatostatin
standard deviation scores for children with cerebral tumours who
responded well to growth hormone therapy during the period of review.
AGV cm/year SRIF SDS
Patients April/85 Jan/8 6 Jan/87 April/85 Jan/96 Jan/87
l.DH 10.6 7.6 6.7 -0.57 -1.07 -0.57
6 .JMcD 5.8 2.1 2.6 +0.50 -0.03 -0.84
7.KT 4.2 1.6 6.5 -1.27 +0.20 -0.60
3.CI/F 4.5 1.7 4.3 +0.76 +0.53 +1.56
4.SD/F 4.0 3.2 3.2 +2.82 +1.49 +2.86
5.AMcC'F 8.1 1.7 6.8 -1.34 +0.24 -0.46
6 .PCF 4.0 1.3 000 -0.57 000 -1.44
Mean ,  5.9 2.7 4 .3 +0.05 +0.22 +0.07
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Table 3.20 The annual growth velocities related to plasma somatostatin 
standard deviation scores for children with cerebral tumours who 
responded less w ell to growth hormone therapy during the period of 
review.
AGV cm/year SRIF SDS
Patients April/85 Jan/8 6 Jan/87 April/85 Jan/8 6 Jan/87
2.DB 7.0 2.7 2.8 -0.37 +0.13 -0.34
3.MM 5.0 2.1 1.8 +0.64 +1.14 +0.67
4.PC 12 5.7 6.0 +1.11 +0.87 +1.74
5.TR 4.8 2.5 5.2 -1.21 -1.71 -0.50
l.LB'F 3.0 2.3 3.0 +1.53 +1.98 +1.60
2.AMcE 3.1 2.3 6.3 +1.07 -1.27 +0.76
Mean 5.8 2.9 4.2 +0.46 +0.36 +0.67
1 5 0
For convenience the means of these standard deviation scores are shown 
in Table 3.21.
The interesting but not unexpected point emerges that all plasma 
concentrations except for threonine in the 'good responders' fell when 
growth hormone was withdrawn and they rose again when treatment was 
restarted. In Table 3.21 all the changing values throughout the three 
observation periods are statistically significant except where indicated (NS).
Dispensable amino acids
The actual plasma concentrations of these amino acids found in these 
'tumour patients' are as has been mentioned before in Appendix Tables 
H I-6 . From these data the standard deviation scores for the plasma 
concentrations have been calculated and are shown in Appendix Tables J.l 
& 2 for both good and bad responders. The means for these standard 
deviation scores are brought together in Table 3.22. It will be noted from 
this Table that uniformly except for tyrosine in the 'good responders', that 
the plasma concentrations as reflected by their SDS's fell on withdrawal of 
growth hormone but rose again on recommencement of treatment. In 
those poor responders tyrosine concentrations continued to fall even after 
restarting the recombinant growth hormone.
Nutritional Ratios
The nutritional ratios for both 'good and poor responders' are shown in 
Appendix Table K. 1 & 2. From these data Table 3.23 has been constructed 
which shows the means of the nutritional ratios together with P values for 
the two groups of patients during the three periods of review. In the 
"good responding" group the fall in nutritional ratios for Rl, R2 and R3 on 
withdrawal of growth hormone treatment were statistically significant; on
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the other hand R4 increased during that period although the rise was not 
significant. The improvement (rise) in the nutritional ratios following the 
recommencement of growth hormone therapy was significant for Rl and 
R2 but not significant for R3, while R4 fell again with recommencement of 
treatment although the fall was not significant.
The corresponding values found for the 'poor responders' again indicated 
that on withdrawal of therapy the falls in Rl, R2 and R3 were significant 
while R4 showed a rise but that rise was not significant. Following the 
resumption of treatment the ratios Rl, R2 and R3 rose but the rise was not 
significant, while R4 fell which fall also was not significant.
The relevance of these trends in the nutritional ratios as calculated from 
the plasma amino acid concentrations will be discussed in Chapter 4.
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Table.3. 21 Means of SDS's for indispensable amino acids plasma 
concentrations in patients with cerebral tumours (good and poor 
responders).
Valine Leucine Isoleucine Threonine Lysine
April/85 +0.06 +0.15 +0.24 -0.13 -0.16
Good
Responders
Jan /8 6 -1.18 -1.11 -0.92 +0.12  "ns" -0.76 "ns"
Jan /87 -0.1 +0.05 +0.71 +0.45 "ns" +0.21
April/85 0.00 +0.22 +0.69 +0.21 +0.09 Poor
RespondersJan /8 6 -1.16 "ns" -0.88 -0.83 -0.01 "ns" -0.84
Jan 187 -0.23 000 +0.40 +0.16 "ns" -0.12
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Table.3.22 Means of SDS's for dispensable amino acids plasma 
concentrations in patients with cerebral tumours (good and poor 
responders).
Alanine Glycine Serine Tyrosine
April/85 -0.03 -0.25 -0.21 +0.52 Good
RespondersJan/8 6 -0.44 -0.82 -0.45 +0.58
Jan/87 -0.31 -0.21 +0.26 +0.38
April/85 +0.20 +0.06 +0.09 +0.53 Poor
RespondersJan /8 6 -0.91 -0.59 -0.34 +0.28
Jan /8 7 -0.18 +0.38 +0.46 -0.12
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CHAPTER FOUR
Before discussing in some detail the results of the investigations as 
presented in the Tables of Chapter 3, I will revert to some topics which 
arose in the earlier Chapters.
The Creutzfeldt-Jacob incident in the history of growth hormone as 
therapy for children with short stature, may have been a fortunate event 
in that it may have accelerated the introduction of recombinant growth 
hormone. However to date I have not read incontrovertible proof that 
those children who allegedly developed the spongiform degenerative 
neurological disease have produced evidence of an anti-viral titre to the 
noxious agent nor has that noxious agent been identified. If cows had 
observed the affected patients would they have labelled them as having 
'mad humans' disease ? After all mad cows' disease is also a spongiform 
degenerative neurological disease and so is scrapie in sheep. It may be in 
time to come there will be a unifying pathology to account for the various 
expressions of inexplicable neurological disease which we recognize in 
children. An example of such unification is the link-up of Letterer-Siwe 
disease, Hand-Schuller-Christian disease and eosinophilic granuloma of 
bone. N ow  these three are regarded as variants of malignant 
reticuloendotheliosis. The cow may yet say, 'What fools these mortals be ?'
Cadaveric growth hormone of the UK variety was produced in a 
Cambridge Laboratory associated with that seat of learning. It was given to 
children by Medical Research Council good intentions but the product was 
never given a 'contents specification' nor did it ever answer the 
requirements of the British Standards Institute - not that the product was 
ever submitted for analyses. However the product is now of historical
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interest but with this reserve. The calves born of mothers or presumably 
fathers with BSE are slaughtered. Can we expect possibly affected children 
born of parents, one or both of whom received cadaveric growth 
hormone? Many of these children are now in the marriageable age or in 
this present era, capable of having and fathering children. Is therefore the 
monitoring of the British cohort of children who received the now  
potentially noxious cadaveric growth hormone sufficiently identified at 
least in some register against future scientific requirements and maybe also 
legal. This would be better done by the official British Paediatric 
Association rather than by a Government Department or the British 
Paediatric Endocrine Society.
The dawn and high noon of the recombinant growth hormone is upon us 
and with characteristic enthusiasm the endocrinologically orientated 
clinicians are bent on ' something to observe7 - that is to say, give it and 
see what happens. And if the growth response is not satisfactory, then let 
us give more - double the dose : a practice detrimental to the coffers of the 
National Health Service, but advantageous to the pharmaceutical 
companies which produce it and may be of some value to the patients.
Different Pharmaceutical Companies use different starting cells. Some use 
a strain of E. coli, others use mouse mammary gland cells. In the final 
extraction the E. coli bodies have to be ruptured to release the hormone at 
least but also may be prions, while the mammary cells release the formed 
growth hormone into the incubation effluent. The extracted product need 
not be as pure as we would like it to be. Only this, it is unlikely to contain 
other trophic hormones, a feature of the cadaveric product. Those Firms 
which use E. coli reassure us that E. coli are free from virus affection. 
However, even at cellular level there is naught for naught. The bacteria
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and the mouse mammary cells have to receive something in return for 
their producing growth hormone after the appropriate amino acid 
sequence is inserted into their plasmids. The Pharmaceutical Companies 
do not reveal the content of their incubation mixtures and what effects the 
total process has on individual compounds in the incubation effluent. 
Perhaps we have to await the occurrence of juvenile or young adult 
Alzheimer's disease or an illness like Huntington's chorea in a child 
without a family history. This might produce career material for a 
neuroendocrinologist.
Another point on which I wish to comment is the number of tests 
available by which isolated growth hormone deficiency may be diagnosed. 
Historically, children were diagnosed as having growth hormone 
deficiency if they did not grow, that is if their annual gains were less than 
60 percent of the normal for their age. Added to such an observation was 
the insulin unresponsiveness test in which the child was given  
intravenously soluble insulin 0.1 iu per kg body weight and the blood 
sugar concentration followed over a 2.5 hour period. Coma, convulsions 
or profound hypoglycaemia not recovering at 2.5 hours was taken as 
supportive evidence of growth hormone deficiency. These were the days 
before growth hormone assay was possible. The advent of RIA method for 
growth hormone assay has not made the definition of growth hormone 
deficiency any more universly agreed. Firstly, there is no agreement on 
the degree of hypoglycaemia to be achieved before the test is valid. How  
then can the response as measured by the subsequent plasma growth 
hormone levels be compared patient with patient or age group with age 
group if the glucoprivation stimulus varies from patient to patient? 
Secondly , there is no great agreement on what minimum plasma growth 
hormone concentrations which must be achieved to justify the terms
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complete and partial growth hormone deficiency. The relevance of this 
latter diagnosis has even been questioned.
In testing for growth hormone lack, as opposed to testing for other growth 
factors such as IGF-I & II, GRF and somatostatin, we are really attempting 
to discover whether or not the problem is in the hypothalamus 
(neurosecretory) or in the pituitary (synthetic). This distinction is 
academic, for growth hormone is the current therapy for both conditions. 
It is true that GRF is available but the present experience is that there is a 
deteriorating response with time.
However in this work I have been concerned with two groups of patients 
with growth hormone deficiency namely those whose deficiency was sui 
generis and the other iatrogenic. My clinical observations strongly suggest 
that the growth hormone deficiency is the only common feature. There 
does seem to be a basic "unwillingness ' of those with the deficiency sui 
generis, to grow whereas those with the deficiency iatrogenic 'want ' to 
grow. In other words there seems to be indefinable impedimenta in those 
sui generis patients which are absent in the iatrogenic group.
Finally on growth hormone, we recognize that it has a plurality of 
functions. I am concerned here with its growth promoting action and its 
interaction with both amino acids and somatostatin. Its other actions may 
be given only brief mention.
There are a few points regarding somatostatin on which I wish to retrench 
or dilate. Somatostatin is very readily destroyed by proteases and hence to 
minimize this trasylol was added to the blood withdrawn for somatostatin 
assay. Nonetheless any losses due to proteases must be common to all 
investigators. But it is surprising that clinical endocrinologists have been
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slow to study CSF somatostatin for here is a biological fluid with an 
exceedingly low concentration of protein and thus eminently suitable for 
study of its somatostatin content.
The actions of somatostatin are many and varied but in this work my 
interest is in its possible reciprocal relationship with growth hormone and 
its direct relationship with plasma amino acid concentrations. But at the 
pituitary level it does in its main action suppress the release of growth 
hormone presumably thereby causing less linear growth when in excess. 
This seems to be the basis for the administration of a somatostatin 
analogue (SMS 201-995) to patients with acromegaly. Indeed there is a 
current trial of administering SMS 201-995 to children with tall stature in 
an attempt to restrict the growth velocity and thus curtail height 
achievement. (148). Additionally high plasma concentrations of 
somatostatin are thought to advance bone maturation (149) and to reduce 
plasma concentrations of IGF-I (150). Since menses in the female is more 
related to osseous maturation than to chronological age then it will be of 
interest when large series of tall children treated with somatostatin are 
published, to observe if the somatostatin induced an earlier onset of 
puberty. This was the problem of oestrogens for tall girls and an 
androgenic anabolic hormone for tall boys although many fewer tall boys 
are offered treatment.
My penultimate statement on somatostatin here concerns the finding that 
infused somatostatin causes an immediate fall in plasma growth hormone 
concentration followed by a rebound peak. Patients with either 
neurosecretory or synthetic growth hormone deficiency would not show  
this phenomenon. If however a short statured child in whom growth 
hormone deficiency were suspected, were firstly tested with the 1-hour
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GRF test and did not respond positively then it could be concluded that 
there was a lack of preformed growth hormone in the pituitary. No 
further test need be done and growth hormone replacement would be 
indicated. If however there was an increase in the plasma growth 
hormone concentration following the GRF test then somatostatin could be 
infused and the expected fall followed be a rise in the plasma growth 
hormone concentration could be sought. A failure to observe the 
phenomenon in a child known to respond to GRF would indicate that the 
original growth hormone deficiency is due to a hypothalamic cause.
The readers of this thesis are respectfully requested to consider this 
suggestion as 'copyright' for a period of 3 years until I have had an 
opportunity to investigate the idea in my own hospital in Tripoli, Libya.
Finally there is work going on in the veterinary field (151)whereby sheep 
are immunized against their own somatostatin. This has resulted in a 
more rapid increase in carcase mass and height. Were this work to be 
extended to children with short stature then it must be essentially reserved 
for those children in whom is demonstrated pathologically high plasma 
concentrations of somatostatin .
N Simple comment but interesting enough are the findings that 
somatostatin inhibits the absorption of xylose and that in patients with 
cystic fibrosis there is a relative increase in the somatostatin-producing 
tissue in the pancreas in both diabetic and non-diabetic patients (152). I 
might hazard a statement on the effects of this latter finding. If this 
histochemically identified increase in somatostatin producing cells are, 
active then the increased plasma somatostatin concentrations in patients 
with cystic fibrosis can do nothing but worsen their clinical status for 
insulin, chymotrypsin and trypsin are all inhibited by somatostatin and so
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is the gut absorption of nutrient. But the delay in gut motility and hence 
the onward passage of nutrient through the gut may provide a longer 
period for gut absorption to make good the enzymic deficiency.
On the subject of plasma amino acids I wish to highlight if perhaps 
reiterate some points . The indispensable amino acids lysine and 
threonine are the only amino acids which are truly nutritionally 
indispensable for they cannot be replaced like other indispensable amino 
acids by their a-keto analogues. The branched chain amino acids are like 
wise important for they are not significantly metabolized in the liver. Of 
the total amino acid nitrogen in the hepatic effluent blood after a meal 70 
percent is due to the branched chain amino acids. These amino acids are 
metabolized and degraded mainly in muscle, kidney and even in the brain 
tissue. Leucine on the other hand is important in that it is a regulator of 
protein turn over, low plasma concentrations stimulating protein 
synthesis while high concentration inhibiting catabolism of tissue 
proteins. The metabolism of these branched chain amino acids in muscles 
results in alanine which is returned to the liver as a glucogenic amino 
acid. It might be expected that when children receive growth hormone as 
therapy that the expected rise in plasma amino acids would be in favour of 
the branched chain amino acids as well as of lysine and threonine and that 
if these are concurrently being built into muscle then there might be an 
increase in the circulating alanine.
Now regarding the cohort of patients studied in this work, 32 were chosen 
from a total of 40 patients. The reason for this selection was that the 8 
patients excluded were from irresponsible families in which either a single 
parent mother who was out working and the child cared for by an 
irresponsible grandmother, or a single parent father who was totally
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inadequate for the task. Others of the 8 children just had unreliable 
parents as judged by the number of non-attendances at the growth clinic 
and by the long periods of time between each request for a further supply 
of growth hormone. It was felt that these 8 children would not be wholly 
representative of good treatment and anthropometric measurements from 
them, if included would certainly skew the data adversely.
We now come to the interesting consideration of the data provided in the 
several Tables of Chapter 3. Let the reader be reminded that almost 
throughout, standard deviation scores were used to express the deviation 
from the mean or 50th. centile which existed for each patient whether with 
reference to height , plasma somatostatin or plasma amino acid 
concentrations. This system was used to eliminate the variations due to 
the age factor. Further while equating patient data with the normal mean 
or 50th. centile I have also used each patient as his own mean as it were as 
he moves with time in relationship to the events taking place at each time 
interval.
Table 3.1 containing data for boys with IGHD shows how each patient's 
height deviated from the normal mean over the 1.75 years of the survey. 
Each patient, following a nine month period without growth hormone 
treatment fell in height further from his mean for chronological age 
(except Patient 14- MMcG who had a better growth rate according to his 
chronological age at that time) through the 'off' period. In so far as the 
height SDS's for January 1986 are not worsened by a factor of -1.0, these 
children therefore did grow but their growth velocity was not sufficient to 
maintain their 'treatment' height SDS's of April, 1985. The seriousness of 
this is that when treatment with growth hormone was restarted, then 
catchup growth had to make good what had not been achieved during the
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period without treatment and in addition to promote further increments 
representing growth for the second treatment year (to January 1987.). This 
was not satisfactorily achieved so that several of the children were even 
shorter at the end of the survey period that is to say- a more negative SDS 
at January 1987 than at April 1985 with reference to the 50th. centile for 
their chronological age at January 1987. Taking the group as a whole it will 
be seen that the mean height SDS of -3.3 at April 1985 after a dip to -3.57 at 
January 1986, did not achieve the April 1985 score and was only -3.35, that 
is to say an overall worsening.
In Table 3.2 are similar data for 5 girls with IGHD. Here it will be observed 
again that the mean height SDS at January 1986 had worsened again not by 
a factor of -1.0 but less and the recovery of the mean height SDS at January 
1987 was greater than 1.0 in Patients 1(SS) and 3 (LB). However the mean 
SDS's for these 5 girls improved during the 1.75 years of observation by 
+0.62 SD's . This is very unimpressive but salutary.
If we now consider the nett changes in annual growth velocities relative 
to the changes in the height SDS's, then in Table 3.3 for males and Table 3.4 
for females it will be seen that during the "off" growth hormone period 
their annual growth velocities were on average less than 4 cm (ie. at 
January 1986) but that on restarting growth hormone the annual growth 
velocities exceeded 6 cm per year. The mean for each group was 6.07 cm 
per year for boys and 8.14 cm per year for girls. But the important point is 
that for the period April 1985 to January 1987 the mean annual growth 
velocity for boys was 4.44 cm per year and for girls 5.87 cm per year. Thus 
the girls seemed to gain more than did boys but neither achieved the mean 
full annual growth velocity over the withdrawal /restart period.
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Another point to be derived from these two Tables is that the mean 
annual growth velocities for the first year of the recombinant growth 
hormone treatment, as well as exceeding those of the withdrawal period 
where also greater than the last year of cadaveric growth hormone therapy. 
Two meanings could be derived from this observation. Firstly it could be 
claimed that recombinant growth hormone is a better stimulus to linear 
growth than was the cadaveric growth hormone. Pharmaceutical 
companies producing the new product would be delighted to think that 
this was entirely so. But it is recognised that the annual growth velocity is 
usually greater in the first year of treatment and it could be considered that 
after nine months without treatment , the patients were as though they 
had not been treated at all. Also the last year of cadaveric growth 
hormone treatment was for several the nth. year of treatment in which the 
annual growth velocity was not expected at any rate to be maximal.
The reader will have observed from the foregoing Tables that some 
children responded better than others. Now consider the "good" and the 
'poor' responders. These two groups are collected firstly into Tables 3.5 and 
3.6 as the good responding boys and girls. From Table 3.5 it will 
immediately be appreciated that the height SDS's at January 1987 were 
improved when compared with the corresponding height SDS's at April 
1985. The means were -3.17 for January 1987 compared with -3.42 at April 
1985. This value of -3.42 at April 1985 fell to -3.53 at January 1986. Thus 
the improvement in height SDS from January 1986 to January 1987 was by 
+0.36 SD's. Thus there was an improvement in height when compared to 
the appropriate 50th centile for age of +0.25 SD's. Bearing in mind that 
these boys all had lost ground during the "off" period the new treatment 
was expected to make good these losses and at the same time to continue
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to produce as normal as possible a growth velocity for the first year of 
treatment with recombinant growth hormone.
In Table 3.6 are the corresponding data for the girls who did well. The 
mean height SDS's for the two periods are -3.31 (April 1985) and -2.48 
(January 1987) which represent a better improvement of +0.83 SD's when 
compared with that for the boys of +0.25 SD's at the same period. These 
girls also showed a worsening of their height data to a mean of -3.45 i.e. a 
fall of -0.14 SD's thus the improvement between January 1986 and January 
1987 was +0.97 SD's. This is even a better response than that for the boys of 
+0.36 SD's.
When we consider the actual losses and gains in terms of the annual 
growth velocities then the"good" responding boys only achieved a mean 
•of 2.98 cm per year during the "off" period and this must be attributed to 
the lack of administered growth hormone. When growth hormone was 
reintroduced the annual growth velocity improved to a mean of 6.4 cm per 
year. Thus over the 1.75 years i.e. April 1985 to January 1987, the mean 
annual growth velocity was 4.69 cm per year which is just above the 60 per 
cent level recognised as representing significant growth failure. The 
efficacy of the recombinant growth hormone may be judged by its ability to 
correct a reduced annual growth velocity and to restore it to normal. 
While this was achieved during the one year of treatment the deficit 
sustained during the "off" period was responsible for the continuing 
negative SDS's.
A similar pattern of annual growth velocity is seen in Table 3.6 (good 
responding girls). A slight fall at January 1986 to 4.27 cm per year was 
restored to 8.40 cm per year at January 1987 due to the restarting of 
recombinant growth hormone. Interestingly here the mean annual
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growth velocity for the 1.75 years of the "off/on" period was 6.34 cm per 
year which clearly is a very good response. This is reflected in the marked 
improved height SDS of -2.48 at January 1987 representing an 
improvement of +0.97 SD's.
We now consider the status of these "poor" responders whose data are in 
Table 3.7. Firstly note that their mean height SDS fell from -2.93 at April 
1985 to -3.42 at January 1986 and rose to -3.34 at January 1987. Even so, the 
mean height SDS at January 1987 was worse than that at April 1985 by a 
mean SDS of -0.41. Thus this group lost in height a SDS of -0.49 through 
lack of growth hormone therapy and on recommencement of therapy 
only gained +0.08 SD's. In summary then these "poor" responders lost 
more through lack of growth hormone and gained less after restarting 
than did either the "good" group of patients (boys and girls).
When we look at their annual growth velocities during the 'off' period the 
means were 2.35 cm per year rising to 5.89 cm per year, thus averaging 4.12 
cm per year over the 1.75 year period. This is almost on the 25th. centile 
for growth velocity and is typical of growth hormone deficiency 
continuing. Maybe in this group of patients an increased schedule of 
growth hormone therapy is required or maybe there are other impeding 
factors to linear growth which if removed or counteracted would permit 
improved linear growth in response to normal treatment.
Let us now consider the plasma concentrations of somatostatin in these 
two groups of patients. These data are in Tables 3.8 & 3.9 where the real 
plasma concentrations of somatostatin are shown for each child with the 
appropriate SRIF SDS's. Immediately it will be seen in Table 3.8 that no 
child had an abnormally high plasma concentration of somatostatin at any 
of the three periods of the survey except Patient 3 LB (girl) at January 1986
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ie at the end of the 'off' period which normalised on recommencement of 
growth hormone therapy. When one considers the mean SDS's for the 
plasma concentrations of somatostatin for these three periods on /o ff/on  
growth hormone, they were +0.69 at 1985 : +0.94 at 1986 and +0.48 at 1987 
i.e normal values well within the +2.5 SD's.
Reference now to Table 3.9 wherein are data for the 'poor 'responders, a 
vastly different set of findings are seen. Most have much higher plasma 
concentrations of somatostatin for age and this is reflected in high SRIF 
SDS's. Several are well above the +2.5 SD level while the means for the 
three periods, on /off/on  growth hormone therapy are +2.32 (1985); +2.76 
(1986) and +2;24 (1987). This immediately suggests that there are two 
types of children with short stature, one with high concentrations of 
plasma somatostatin and the other with normally low concentrations. The 
question now is whether or not high plasma concentrations of 
somatostatin impede normal linear growth? If this were so, then the 
action of the somatostatin need not only be at the pituitary level for these 
children have already growth hormone deficiency. Is it that the high 
plasma somatostatin concentrations act at gut level to prevent the 
absorption of amino acids which themselves are the building bricks for 
protein metabolism and the provision of substrate on which the linear 
growth of bone and muscles depend?
Note that during the 'off' period of treatment the mean plasma 
somatostatin SDS was abnormally high. If this concentration of 
somatostatin were to act at the pituitary level then there would be a 
suppression of any releasable growth hormone from the pituitary and if 
one adverts to Table 3.11 the annual growth velocity for this 'poor 
'responding group of children fell to 2.34 cm per year during the 'off
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treatment' period. This was the lowest mean annual growth velocity 
observed. Thus there would be a prima facie case to attribute failure to 
grow to the high plasma concentrations of somatostatin.
This idea is not altogether fantasy for IGF-I plasma concentrations have 
been used as a marker to indicate which group of children will grow in 
response to growth hormone therapy. Combine this with the recent 
finding (149) that administration of somatostatin analogue (SMS 201995) 
results in a fall in the plasma concentration of IGF-I then a reduction in 
linear growth associated with high plasma somatostatin concentrations is 
easily accepted. Somatostatin analogue when given to acromegalic patients 
also results in a decrease in the plasma concentration of IGF-I. My finding 
is that high plasma concentrations of somatostatin are associated with 
failure to grow in response to growth hormone. The question now is 
whether or not the patients' plasma somatostatin status is the all 
important item in this difficult situation.
Interestingly on this score, are the animal experiments (151) which show  
that immunization against somatostatin resulted in increased weight and 
height in lambs so immunized and at the human level somatostatin 
analogue (SMS 201995) has recently been used to control height in tall 
children (148,149).
It is easy to suggest that those children with growth hormone deficiency 
who do not respond well to growth hormone therapy and who have high 
plasma concentrations of somatostatin should be immunized against 
somatostatin? There are dangers in such a thought for surely some of the 
good inhibitory effects of somatostatin are necessary for the body economy. 
Nonetheless if it were possible to suppress the plasma concentrations of 
somatostatin in these children in whom the concentrations are high then
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an opportunity for increased linear growth would be won. Certain amino 
acids infused intravenously have been reported to suppress plasma 
concentrations of somatostatin (153, 154). Herein may be another approach 
to the treatment of children with short stature. Thus it emerges that the 
assay of the plasma concentration of somatostatin must be included in the 
standard investigations of children with short stature when growth 
hormone deficiency and replacement therapy are contemplated.
But to provide some information on the relationship of plasma 
somatostatin concentrations and those of plasma amino acids I now  
present plasma amino acid concentrations for the patients considered in 
this work.
In Table 3.14 are the mean SDS's for the indispensable amino acids for both 
the 'good' and 'poor' responders and in Table 3.15 are the corresponding 
mean values for the dispensable amino acids. From these Tables we note 
that at no time were the plasma concentrations of either group of amino 
acids, in either the 'good' or 'poor' responders significantly abnormal. 
Nonetheless during the 'off' growth hormone period the plasma 
indispensable amino acid concentrations were reduced in all except for 
threonine whose plasma concentration increased. A similar trend was 
noted for the plasma dispensable amino acids in all except for tyrosine 
which rose during the 'off' period.
On restarting growth hormone, uniformly the concentrations of all the 
indispensable amino acids rose except for threonine in both 'good' and 
'poor' responders. A similar trend is seen for the dispensable amino adds 
all of which except tyrosine increased in their plasma concentrations. 
Additional to the above observation it is notable that in the 'poor'
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responders these plasma concentrations of amino acids were lower than in
the 'good' responders.
Interestingly some of these findings agree with published work. It has 
been shown (155), before that following a one year period of treatment of 
IGHD patients with growth hormone, plasma concentrations of threonine 
were reduced while the concentrations of other amino acids were 
significantly increased.
At this stage it might be reasonable to make some conclusions concerning 
the relationship between the plasma concentrations of somatostatin and 
those of the amino acids. As we have noted, some patients with high 
plasma concentrations of somatostatin do not grow as satisfactorily as 
those with normal plasma concentrations even with the administration of 
growth hormone. Those patients with high plasma somatostatin 
concentrations have lower plasma concentrations of amino acids than do 
those children whose plasma concentration of somatostatin is normal. 
The means of the SDS's for the amino acids for both the indispensable and 
dispensable amino acids have been collected together with the respective 
SDS's for plasma somatostatin into Tables 4.1&4.2 (p.181-182) so as to show  
the relationships between the plasma somatostatin and the plasma amino 
acids. It will be remembered that all the patients experienced a period of 
'on /off/on ' growth hormone therapy. What did vary between the two 
groups was that the 'good' responders had on average low normal plasma 
somatostatin SDS's whereas the 'poor' responders had high normal or even 
abnormally high plasma somatostatin SDS's especially during the 'off' 
growth hormone period. Thus plasma somatostatin must act in these 
children at two sites viz. to inhibit the release of growth hormone at the
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pituitary level and to restrict the absorption of nutrient in the form of 
amino acids. Clearly there are two types of patients in my cohort.
Concerning growth hormone therapy I have not found any reference to 
this very interesting and important observation that first, some growth 
hormone deficient children have a high plasma som atostatin  
concentration while others do not and in this regard, those whose plasma 
somatostatin concentration are high have lower concentrations of plasma 
amino acids while those with a normal plasma concentration of 
somatostatin have higher plasma amino add concentration. This cannot 
be without significance in terms of substrate for linear growth. But it 
might be relevant to consider here that those children whose plasma 
somatostatin concentration is high may require an increased dosage of 
growth hormone as a therapy when compared with their counterparts. Or 
would it be for this group that immunization against somatostatin should 
be explored?
Now regarding the Nutritional Ratios the reader is referred again to the 
Appendix Tables B 1-6 for the 'good' responders and to Appendix Tables B 
7-9 for the 'poor' responders. Herein are the actual plasma amino acid 
concentrations. In Appendix Tables E 1&2 are the Nutritional Ratios 
calculated from the real plasma amino acid concentrations. Let us now  
consider the significance of these ratios. In a sense these make a tale that is 
told.
During the 'off' growth hormone period Ratios 1, 2 & 3 were reduced and 
we know that the actual plasma concentrations of amino acids used to 
calculate these ratios had fallen during that period. The numerator in 
Ratios 1&2 are the sums of the branched chain amino acids and in Ratio 3 
the numerator is valine. The denominator in Ratios 1, 2&3 are
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dispensable amino acids and since the ratios fell during the 'off' period it 
follows that most affected by the withdrawal of growth hormone was the 
concentrations of the branched chain amino acids. It is therefore likely 
that this fall in the ratio values is due to the unopposed (by growth 
hormone) action of the plasma somatostatin. Does this finding indicate 
that there is a competitive antagonism at the gut level between growth 
hormone and somatostatin? This suggestion is novel.
Ratio 4 is interesting in that the tyrosine increased during the 'off' period 
and this was reflected in a higher value at that stage with a fall when 
growth hormone therapy was current. Could this indicate that another 
metabolic hormone was being brought into action viz. thyroxine requiring 
more tyrosine, to compensate for the loss of growth hormone? It is of 
interest that it has been found that if tyrosine is fed in excess, 
phenylalanine requirement is reduced. (156) This means that a 
conditionally indispensable amino acid like tyrosine can compensate to 
some extent for the parent amino add.
When we come to consider those patients who were short stature due to 
their having had a cerebral tumour, it is interesting that we are dealing 
with an older age group of patients. The total number of "tumour" 
patients was 13 (7 boys& 6 girls) whose age range was 9.37 years to 17,94 
years. There were no cases in this group who had had leukaemia. 
Nonetheless the fact that there were 19 patients with IGHD, and 13 patients 
with tumours, highlights the trend in the nature of paediatric illness, 
namely the increase in tumour/malignant disease. But another reason for 
the absence of post-treatment leukaemia patients is that it is customary to 
have at least 5-year survival period for children with leukaemic malignant 
disease before considering the disease "cured" so as to justify growth
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hormone treatment. The greatest number of these "tumour" patients (7 
out of 13) had craniopharyngioma. Three had medulloblastoma, two had 
glioma (optic and pontine) and one had a retinoblastoma. This is not in 
agreement with general experience for the commonest intracranial 
tumour in childhood is the cerebellar medulloblastoma. Indeed it is stated 
that only 5 to 13 per cent are account for by craniopharyngioma. But my 
series is small enough not to show the recognised trends.
Intracranial tumours may affect the infundibular stalk. Such is the case 
with craniopharyngiomas, but in addition subsequent irradiation is likely 
to damage the hypothalamic nuclear aggregates which elaborate the 
releasing horm ones, whether the irradiation is g iven  for 
craniopharyngiomas or for other tumours most commonly for the 
cerebellar medulloblastoma .
Once again the "tumour"patients were divided into those who over the 
period of review improved their height SDS's and those who did not. 
Firstly in those who improved (Table 3.17) (6 of 7 had craniopharyngioma), 
some certainly were extremely short statured at the beginning of the 
review period (patients 6 & 7 "boys" and 3&4 "girls") but on average with a 
mean height SDS of -1.97. They were not as short statured as the good 
group of the idiopathic patients whose mean height SDS was -3.42. During 
the "off" growth hormone period there was no loss of height status and 
on restarting growth hormone a small mean catchup growth was reflected 
for each patient in a mean of -1.44. height SDS.
The "poor" responding group (Table 3.18) (only one craniopharyngioma) 
with a starting height SDS of -2.09 worsened during the "off" growth 
hormone period to -2.67 and even on restarting growth hormone their 
mean height SDS worsened further to -2.91. All of those children at 1987
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were significantly short statured (except patient LB "girl"). Thus it would 
appear that patients with a craniopharyngioma are likely to fare better in 
terms of height in response to growth hormone than those with 
medulloblastoma or glioma. Why this should be is unclear
From my reasoning regarding the IGHD patients one might expect that the 
"good"and "poor" responders of the tumour group would show the same 
trends in their plasma somatostatin concentration. This was not so 
(Tables 3.19.and 3.20 ) for throughout the period of review (1.75 years) the 
SDSs' for plasma somatostatin were entirely normal except for patient 4.SD 
(female) whose plasma somatostatin concentration was significantly 
abnormally high at April 1985 and January 1987 these being periods of 
growth hormone administration. Combine this observation with her 
height SDS's at these periods, it will be seen that she is grossly 
underheight. It is therefore suggested that this girl was on course for short 
stature due to high plasma somatostatin concentrations before her cerebral 
tumour developed. This girl had only had two years of growth hormone 
therapy and after removal of her medulloblastoma she had irradiation 
therapy but had she been of normal height, then it is unlikely that within 
two years she lost so much height to have a height SDS of -4.36 when 
growth hormone was withdrawn. This patient's example reinforces the 
earlier suggestion that all patients who are short statured, without other 
obvious reason should have the plasma somatostatin concentration 
assayed.
In Tables 3.21.and 3.22 are the mean SDS's for the indispensable and 
dispensable amino acids in this tumour group of patients. It will be seen 
that at all times these values were normal. But there was a lowering of the 
concentration both for the indispensable and the dispensable amino acids
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except for threonine at January 1986 and tyrosine at the same period. These 
latter trends were only seen in the 'good 'responders.
Thus for this tumour group there is (a) normal plasma concentration of 
somatostatin (b) normal plasma amino acid concentrations and despite 
these similarities we have two subgroups behaving differently in relation 
to growth, one improving and one worsening. The only differentiating 
factor is the pathology in that those who do show some linear growth 
during the period of observation have a craniopharyngioma. Only one of 
those children who did not grow satisfactorily had a craniopharyngioma. 
The question is whether or not medulloblastoma and glioma have as yet 
indefinable growth restricting actions.
In Table 3.23 are the changes in the nutritional ratios of the "tumour" 
group. A similar trend is here appreciated like unto IGHD group. The fall 
in the ratios at January 1986 was due to greater fall in the indispensable 
amino acids than occured in the dispensable amino acid concentrations. 
For what the comparison is worth, the 'good" responders had a higher 
ratios in general. The p-values show where the changes were statistically 
significant.
To summarize the review of the data which were available to me, I have 
tried to assess the advantage to each of the subgroups ("good"and "poor" 
responders within the two main groups of patients "IGHD" and 
"tumours") of the introduction of recombinant growth hormone.
In Appendix Tables L. 1&2 are the annual advances in osseous maturation 
experienced by each patient during the first year of the new treatment. I 
have abstracted the mean annual bone maturation score for each group of 
patients into Table 4.3.(p.l83) The data are of considerable interest. It will 
be seen that the children with IGHD who responded well in their linear
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growth had a bone advancement of 1.23 years per year while those children 
who had a poor growth response advanced their bone age by only 0.74 
years per year. Those children with cerebral tumours whether "good" or 
"poor" responders advanced their bone age by 0.94 and 0.86 years per year 
respectively.
I concluded that those "poor" responders in the IGHD group, although 
their linear growth were unsatisfactory, their slow bone maturation 
compensated to a certain extent by permitting more bone age years for 
growth. Thus in a sense the "good"responders were disadvantaged to 
some extent by their rapid osseous maturation. It is very worthy of note 
that these "poor" responders in linear growth and osseous maturation 
were the only children with high plasma concentrations of somatostatin. 
Can it be concluded that somatostatin may antagonise the action of growth 
hormone at the epiphyseal growth plate? Although I am concerned with 
the interactions of growth hormone and somatostatin I am aware that 
other factors may require to be considered such as thyroxine and 
androgenic anabolic hormones but these cannot be discussed here. 
However a fairly recent article from Japan (157) suggests that in the 
management of children with growth hormone deficiency especially of 
those who are nearing puberty, there is a role for a drug which will 
suppress gonadal function (cyproterone acetate and medroxyprogesterone) 
so reducing bone maturation and permitting an increased period for linear 
growth in response to growth hormone. These authors have reported that 
such treatment prolongs the duration of puberty and so improves the final 
height. According to my findings as above given it may be of some 
advantage to those children who although growing well but with an 
advancing bone maturation that they may should also have an 
antigonadotrophin so as to prevent or reduce the advancement in bone
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age giving them more time for linear growth in terms of bone age years . 
By this we may be able to improve their final height.
It is tempting to continue a discussion by raising suggestions new and old 
and to apply these to the argument. Little is to be achieved however by so 
doing. But at the end of this work it is pertinent that I ask myself if I have 
been guilty of a manner of research which I earlier criticized "Let us do 
something and watch the effects ".
The Creutzfeldt-Jacob incident did happen rightly or wrongly. Perforce the 
cadaveric growth hormone had to be withdrawn. There was no substitute 
available widely and necessarily those affected children had a period 
without growth hormone therapy. Then came the recombinant product, 
methionyl growth hormone and continuous treatment was again 
available. The dosage schedule was similar to that used with the cadaveric 
product. That is where I came in - as it were and I have simply observed 
these children throughout their 'on/off/on ' growth hormone treatment. 
Something was done and I have followed the effects. Hopefully however I 
have added something to our knowledge of the behaviour (clinical and 
biochemical) of some aspects of the changes which took place. It is 
probably a truism, but one finding was that once growth hormone is 
started as treatment it must be continued otherwise to stop it will result in 
a return to a phase of growth failure which in some will only be reversed 
with difficulty.
Clinicians managing children of short stature who are being treated with 
growth hormone are aware that some respond better than others. I have 
offered a reason for this. In my cohort of patients those who did not show  
the same degree of linear growth as their peers had higher and sometimes
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abnormally high plasma concentrations of somatostatin. But someone 
may say , "plasma somatostatin ?' Yes, for the pituitary is bathed with 
systemic blood via the long and short pituitary portal vessels which are 
radicles of the hypophyseal arteries. Hence the adenotrophs under a more 
intense continuous tonic suppression of growth hormone release may not 
respond to our insulin hypoglycaemia test which may wrongly cause us to 
label these children as having growth hormone deficiency. How can we 
prevent either these high plasma concentrations of somatostatin or the 
actions of these high concentrations?
The plasma amino acids studied in this work were basically within normal 
during the changing routine, but for all the patients studied here during 
the "off" period of growth hormone treatment the indispensable amino 
acids valine, leucine, isoleucine and lysine concentration fell but recovered 
on restarting growth hormone therapy. The same was true of the 
dispensable amino acids alanine, glycine and serine. Has this any 
significance? I have concluded that this fall in plasma amino acids was due 
to the unopposed action of the plasma somatostatin during the withdrawal 
of growth hormone therapy. However in those children with IGHD who 
fared less well, the fall in the plasma amino acid concentrations was 
greater and the rise in plasma somatostatin also greater.
Protein is necessary for normal growth in children, and the amino acids 
are the the building blocks for proteins. It may then not be surprising that 
the period of reduced linear growth of these patients was associated with a 
lowering of the plasma concentration of some amino acids. The 
therapeutic challenge would therefore seem to be that rational therapy for 
children with growth hormone deficiency can only be maximized if the 
plasma somatostatin status is known for each child. There is no logic in
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increasing the growth hormone schedule if there is a built-in mechanism 
which is obviating optimum utilization of growth hormone. Even 
although I have only shown gains in mean height SDS's of +0.25, and 
+0.83 in the good responders for both males and females respectively (Table 
3.5 and 3.6 p 124&125), that has to be compared with a loss of 0.41 SDS's 
when plasma somatostatin was high (Table 3.7 p 126). I therefore 
concluded that high plasma somatostatin concentration not only prevent 
optimum linear growth in response to growth hormone therapy, but 
attempts must be made to reduce the effects of these high concentrations. 
Does this mean immunization against somatostatin for at least some of 
these children ?
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Table 4.1 Means of SDS for indispensable amino acids in relation to SRIF
SDS for both good and poor responders during the period of review.
Valine Leucine Isoleucine Threonine Lysine SRIF
Apr/85 +0.09 -0.20 -0.11 -0.34 +0.08 +0.69 Good
respondersJan/8 6 -1.15 -1.08 -0.96 +0.14 -0.83 +0.94
Jan/87 -0.01 -0.18 +0.25 -0.14 +0.37 +0.48
Apr/85 -0.45 -0.37 -0.18 -0.58 -0.38 +2.32 Poor
respondersJan/8 6 -1.16 -0.85 -0.19 -0.20 -0.61 +2.76
Jan/87 -0.19 -0.27 -0.34 -0.39 +0.06 +2.24
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Table 4.2 Means of standard deviation scores for dispensable amino acids
related to SRIF SDS in both good and poor responders during the period of
review.
Alanine Glycine Serine Tyrosine SRIF
April/8 ' -0.05 -0.12 +0.12 +0.30
+0.69 Good
respondersJan /  86 -0.79 -0.45 -0.40 +0.58
+0.94
Jan / 8  7 +0.13 -0.17 -0.01 +0.15
+0.48
April/8 ' -0.63 -0.21 -0.30 -0.61 +2.32 Poor
respondersJan /8 6 -0.87 -0.62 -0.45 -0.05 +2.76
Jan /87 -0.57 -0.09 -0.01 -0.35 +2.24
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Table 4.3 Mean of the bone age (years) advancement during one year of 
recombinant growth hormone treatment.
IGHD Tumours
Good
responders
Poor
responders
Good
responders
Poor
responders
Males 1.03 0.80 0.83 0.89
Females 1.65 0.40 (one girl) 1.03 0.80
Total 1.23 0.74 0.94 0.86
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Table-G 1. Actual plasma somatostatin concentrations (pg/m l), and their
standard deviation scores for those children with cerebral
tumours who fared well during the period of review.
April 1985 January 1986 January 1987
Patient SRIF
conc.
SDS SRIF
conc.
SDS SRIF
conc.
SDS
l.DH 15 -0.57 13 -1.07 14 -0.57
6 .JMcD 16 +0.50 14 -0.03 11 -0.84
7.KT 10 -1.27 14 +0.20 11 -0.60
3.CL ’F 18 +0.76 17 +0.53 19 +1.56
4.SD 'F 23 +2.82 19 +1.49 22 +2 .86
5.AMcC *F 11 -1.34 15 +0.42 12 -0.46
6 .PC F 12 -0.57 13 000 8 -1.44
Mean +0.05 +0 .22 +0.07
2 0 6
Table-G 2. Actual plasma somatostatin concentrations (pg/m l), and their
standard deviation scores for those children with cerebral
tumours who fared less well during the period of review.
April 1985 January 1986 January 1987
Patients SRIF
conc.
SDS SRIF
conc.
SDS SRIF
conc.
SDS
2.DB 15 -0.37 16 +0.13 14 -0.34
3.MM 18 +0.64 19 +1.14 17 +0.67
4.PC 19 +1.11 18 +0.87 20 +1.74
5.TR 12 -1.21 10 -1.71 13 -0.50
l.LB 'F 23 +1.53 24 +1.98 22 +1.60
2.AMcC'F 20 +1.07 16 -0.27 18 +0.76
Mean +0.59 +0.36 +0 .66
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Table L.1 Bone age (year) at 1986 and 1987 and its advancement during the 
one year period for the patients with IGHD.'
Patients 1986 1987 BA advance/y
l.AB 1.2 2.5 1.3
2.JC 9.2 9.8 0.6
3.AG 9.3 9.9 0.6
4.A1B 8.1 9.0 0.9
5.NMcQ 12.9 13.5 0.6
6 .CMcG 10.9 13.4 2.5
7.RH 11.7 13.0 1.3
8 .CG 10.8 11.7 0.9
9.NC 14.1 15.0 0.5
10.SS 8.7 9.0 0.3
11.BL 11.6 11.8 0.2
12.IMcC 11.8 14.4 2.6
13.DB 17.7 18.0 0.3
14.NMCG 16.6 17.0 0.4
l.SS"F" 5.0 6.2 1.2
2.CS"F" 5.6 7.3 1.7
3.LB"F" 4.8 7.2 2.4
4.TG"F" 11.8 12.2 0.4
5.AQ"F" 10.6 11.9 1.3
2 2 0
Table L.2  Bone age (years) of tumour patients at 1986 and 1987 and its 
advancement during the one year of recombinant growth hormone 
treatment.
Patients 1986 1987 BA advance/y
l.DH 13.4 13.8 0.4
2.DB 14.1 15.6 1.5
3.MM 16.3 16.9 0.6
4.PC 14.4 15.17 0.77
5.TR 12.3 13.0 0.70
6 .JMcD 13.3 14.0 0.70
7.KT 12.5 13.9 1.4
l.LB"F' 9.0 10.0 1.0
2.AMcE"F" 9.3 9.9 0.6
3.CL"F" 11.6 13.0 1.4
4.SD"F" 11.6 12.5 0.9
5.AMcC"F" 13.0 13.9 0.9
6.PC F 12.2 13.1 0.9
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